<!DOCTYPE html>
<html>
  <head>
    <meta charset='utf-8'>
    <title>A Minimum Representation of Potential Drug-Drug Interaction Knowledge and Evidence - Technical and User-centered Foundation</title>
    <script 
      src='https://www.w3.org/Tools/respec/respec-w3c-common' 
      class='remove'>
    </script>
    
    <script class='remove'>
      var respecConfig = {
      localBiblio: {
      "abarca-2004": {
      "authors": [
      "Jacob Abarca",
      "Daniel Malone",
      "Edward Armstrong",
      "Amy Grizzle",
      "Philip Hansten",
      "Robin Van, Bergen",
      "Richard Lipton"],
      "title": "Concordance of severity ratings provided in four drug interaction compendia",
      "publisher": "Journal of the American Pharmacists Association: JAPhA",
      "pages": "136-141",
      "date": "April 2004",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/15098847"},


      "ayvaz-2015": {
      "authors": [
      "Serkan Ayvaz",
      "John Horn",
      "Oktie Hassanzadeh",
      "Qian Zhu",
      "Johann Stan",
      "Nicholas Tatonetti",
      "Santiago Vilar",
      "Mathias Brochhausen",
      "Matthias Samwald",
      "Majid Rastegar-Mojarad",
      "Michel Dumontier",
      "Richard Boyce"],
      "title": "Toward a complete dataset of drug-drug interaction information from publicly available sources",
      "publisher": "Journal of Biomedical Informatics",
      "pages": "206-217",
      "date": "Jun 2015",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/25917055"},

      "bottiger-2009": {
      "authors": [
      "Ylva Bottiger",
      "Kari Laine",
      "Marine Andersson",
      "Tuomas Korhonen",
      "Bjorn Molin",
      "Marie-Louise Ovesjo",
      "Tuire Tirkkonen",
      "Anders Rane",
      "Lars Gustafsson",
      "Birgit Eiermann"],
      "title": "{SFINX}-a drug-drug interaction database designed for clinical decision support systems",
      "publisher": "European Journal of Clinical Pharmacology",
      "pages": "627-633",
      "date": "Jun 2009",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/19205683"},

      "bender-2013": {
      "authors": [
      "D. Bender",
      "K. Sartipi"],
      "title": "HL7 FHIR: An Agile and RESTful approach to healthcare information exchange",					
      "pages": "326-331",
      "date": "June 2013",
      "href": "http://ieeexplore.ieee.org/document/6627810/?reload=true"},

      "bristol-myers-warfarin": {
      "authors": ["Bristol-Myers Squibb"],
      "title": "{DailyMed} - {COUMADIN}- warfarin sodium tablet",
      "href": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91934a0-902e-c26c-23ca-d5accc4151b6",},

      "brochhausen-2014": {
      "authors": [
      "Mathias Brochhausen",
      "Jodi Schneider",
      "Daniel Malone",
      "Philip Empey",
      "R. Hogan",
      "Richard Boyce"],
      "title": "Towards a foundational representation of potential drug- drug interaction knowledge",
      "pages": "16",
      "href": "http://ceur-ws.org/Vol-1309/paper2.pdf"},

      "boyce-2013": {
      "authors": [
      "Richard Boyce",
      "John Horn",
      "Oktie Hassanzadeh",
      "Anita De Waard",
      "Jodi Schneider",
      "Joanne Luciano",
      "Majid Rastegar-Mojarad",
      "Maria Liakata"],
      "title": "Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness",
      "publisher": "Journal of Biomedical Semantics",
      "pages": "5",
      "href": "https://jbiomedsem.biomedcentral.com/track/pdf/10.1186/2041-1480-4-5?site=jbiomedsem.biomedcentral.com"},

      "califf-2016": {
      "authors": [
      "Robert Califf",
      "Melissa Robb",
      "Andrew Bindman",
      "Josephine Briggs",
      "Francis Collins",
      "Patrick Conway",
      "Trinka Coster",
      "Francesca Cunningham",
      "Nancy De', u'Lew",
      "Karen DeSalvo",
      "Christine Dymek",
      "Victor Dzau",
      "Rachael Fleurence",
      "Richard Frank",
      "J. Gaziano",
      "Petra Kaufmann",
      "Michael Lauer",
      "Peter Marks",
      "J. McGinnis",
      "Chesley Richards",
      "Joe Selby",
      "David Shulkin",
      "Jeffrey Shuren",
      "Andrew Slavitt",
      "Scott Smith",
      "B. Washington",
      "P. White",
      "Janet Woodcock",
      "Jonathan Woodson",
      "Rachel Sherman"],
      "title": "Transforming Evidence Generation to Support Health and Health Care Decisions",
      "publisher": "New England Journal of Medicine",
      "pages": "2395-2400",
      "date": "December 15, 2016",
      "href": "http://www.nejm.org/doi/pdf/10.1056/NEJMsb1610128"},

      "cdc-faststats": {
      "authors": ["CDC. FASTSTATS"],
      "title": "FastStats",
      "href": "https://www.cdc.gov/nchs/fastats/emergency-department.htm"},

      "ansm-2016": {
      "authors": ["ANSM"],
      "title": "Thesaurus des interactions medicamenteuses",
      "date": "2016",
      "href": "http://ansm.sante.fr/var/ansm_site/storage/original/application/de444ea9eb4bc084905c917c902a805f.pdf"},

      "ctcae-wiki": {
      "authors": ["NCI"],
      "title": "What is Common Terminology Criteria for Adverse Event (CTCAE)?",
      "href": "https://wiki.nci.nih.gov/display/VKC/Common+Terminology+Criteria+for+Adverse+Events"},
      
      "fda-cfr-21-4": {
      "authors": ["FDA"],
      "title": "CFR - Code of Federal Regulations Title 21, Volume 4",
      "href": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.57"},

      "dechanont-2014": {
      "authors": [
      "Supinya Dechanont",
      "Sirada Maphanta",
      "Bodin Butthum",
      "Chuenjid Kongkaew"],
      "title": "Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis",
      "publisher": "Pharmacoepidemiology and Drug Safety",
      "pages": "489-497",
      "date": "May 2014",
      "href": "http://www.ncbi.nlm.nih.gov/pubmed/24616171"},

      "drugs-interaction": {
      "authors": ["Drugs.com"],
      "title": "Drug Interaction Report",
      "href": "https://www.drugs.com/interactions-check.php?drug_list=1310-0%2C2311-0&professional=1&types%5B%5D=major"},

      "european-medicines-2012": {
	  "authors": ["European Medicines Agency"],
	  "title": "Guideline on the investigation of drug interactions",
	  "pages": "59",
	  "date": "Jun 2012",
	  "href": "http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf"},

      "fung-2017": {
      "authors": [
      "Kin Fung",
      "Joan Kapusnik-Uner",
      "Jean Cunningham",
      "Stefanie Higby-Baker",
      "Olivier Bodenreider"],
      "title": "Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support",
      "publisher": "Journal of the American Medical Informatics Association: JAMIA",
      "pages": "806-812",
      "date": "Jul 01, 2017",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/28339701"},

      "gaziano-2016": {
      "authors": [
      "John Gaziano",
      "John Concato",
      "Mary Brophy",
      "Louis Fiore",
      "Saiju Pyarajan",
      "James Breeling",
      "Stacey Whitbourne",
      "Jennifer Deen",
      "Colleen Shannon",
      "Donald Humphries",
      "Peter Guarino",
      "Mihaela Aslan",
      "Daniel Anderson",
      "Rene LaFleur",
      "Timothy Hammond",
      "Kendra Schaa",
      "Jennifer Moser",
      "Grant Huang",
      "Sumitra Muralidhar",
      "Ronald Przygodzki",
      "Timothy O'Leary"],
      "title": "Million Veteran Program: A mega-biobank to study genetic influences on health and disease",
      "publisher": "Journal of Clinical Epidemiology",
      "pages": "214-223",
      "date": "February 2016",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/26441289"},

      "hanna-2013": {
      "authors": [
      "Josh Hanna",
      "Eric Joseph",
      "Mathias Brochhausen",
      "William Hogan"],
      "title": "Building a drug ontology based on {RxNorm} and other sources",
      "publisher": "Journal of Biomedical Semantics",
      "pages": "44",
      "date": "Dec 18, 2013",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/24345026"},

      "hennessy-2016": {
      "authors": [
      "S. Hennessy",
      "C. Leonard",
      "J. Gagne",
      "J. Flory",
      "X. Han",
      "C. Brensinger",
      "W. Bilker"],
      "title": "Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions",
      "publisher": "Clinical Pharmacology and Therapeutics",
      "pages": "92-100",
      "date": "Jan 2016",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/26479278"},

      "herrero-zazo-2015": {
      "authors": [
      "Maria Herrero-Zazo",
      "Isabel Segura-Bedmar",
      "Janna Hastings",
      "Paloma Martinez"],
      "title": "DINTO: Using OWL Ontologies and SWRL Rules to Infer Drug-Drug Interactions and Their Mechanisms",
      "publisher": "Journal of Chemical Information and Modeling",
      "pages": "1698-1707",
      "date": "Aug 24, 2015",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/26147071"},

      "herrero-zazo-2016": {
      "authors": [
      "Maria Herrero-Zazo",
      "Isabel Segura-Bedmar",
      "Paloma Martinez"],
      "title": "Conceptual models of drug-drug interactions: A summary of recent efforts",
      "publisher": "Knowledge-Based Systems",
      "pages": "99-107",
      "date": "December 15, 2016",
      "href": "http://www.sciencedirect.com/science/article/pii/S0950705116303896"},

      "hines-2011": {
      "authors": [
      "Lisa Hines",
      "John Murphy",
      "Amy Grizzle",
      "Daniel Malone"],
      "title": "Critical issues associated with drug-drug interactions: highlights of a multistakeholder conference",
      "publisher": "American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists",
      "pages": "941-946",
      "date": "May 15, 2011",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/21546646"},
      
      "institute-medicine-2006": {
      "authors": ["Institute of Medicine"],
      "title": "Preventing Medication Errors",
      "date": "July 2006",
      "href": "https://www.nap.edu/catalog/11623/preventing-medication-errors"},

      "magro-2012": {
      "authors": [
      "Lara Magro",
      "Ugo Moretti",
      "Roberto Leone"],
      "title": "Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions",
      "publisher": "Expert Opinion on Drug Safety",
      "pages": "83-94",
      "date": "Jan 2012",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/22022824"},

      
      "mandel-2016": {
      "authors": [
      "Joshua Mandel",
      "David Kreda",
      "Kenneth Mandl",
      "Isaac Kohane",
      "Rachel Ramoni"],
      "title": "SMART on FHIR: a standards-based, interoperable apps platform for electronic health records",
      "publisher": "Journal of the American Medical Informatics Association: JAMIA",
      "pages": "899-908",
      "date": "Sep 2016",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/26911829"},


      "masclee-2014": {
      "authors": [
      "Preciosa Coloma",
      "Gini  Rosa",
      "Ron Herings",
      "Ernst Kuipers",
      "Gwen Masclee",
      "Giampiero Mazzaglia",
      "Lars Pedersen",
      "Gino Picelli",
      "Silvana Romio",
      "Martijn Schuemie",
      "Lorenza Scotti",
      "Miriam Sturkenboom",
      "Vera Valkhoff",
      "Maria de Ridder",
      "Johan van der Lei"
      ],
      "title": "Risk of upper gastrointestinal bleeding from different drug combinations.",
      "publisher": "Gastroenterology",
      "pages": "784-792.e9",
      "date": "October 2014",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/24937265"},

      
      "mille-2007": {
      "authors": [
      "Frederic Mille",
      "Patrice Degoulet",
      "Marie-Christine Jaulent"],
      "title": "Modeling and acquisition of drug-drug interaction knowledge",
      "publisher": "Studies in Health Technology and Informatics",
      "pages": "900-904",
      "date": "2007",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/17911846"},

      "nabovati-2017": {
      "authors": [
      "Ehsan Nabovati",
      "Hasan Vakili-Arki",
      "Zhila Taherzadeh",
      "Mohammad Saberi",
      "Ameen Abu-Hanna",
      "Saeid Eslami"],
      "title": "A survey of attitudes, practices, and knowledge regarding drug-drug interactions among medical residents in Iran",
      "publisher": "International Journal of Clinical Pharmacy",
      "pages": "560-568",
      "date": "Jun 2017",
      "href": "www.ncbi.nlm.nih.gov/pubmed/28382584"},

      "dailymed-about": {
      "authors": ["DailyMed"],
      "title": "DailyMed - About",
      "href": "https://dailymed.nlm.nih.gov/dailymed/about-dailymed.cfm"},

      "nebeker-2004": {
      "authors": [
      "Jonathan Nebeker",
      "Paul Barach",
      "Matthew Samore"],
      "title": "Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting",
      "publisher": "Annals of Internal Medicine",
      "pages": "795-801",
      "date": "May 18, 2004",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/15148066"},

      "ahrq-drug-drug": {
      "authors": ["AHRQ"],
      "title": "Drug-drug interactions: percentage of patients who received a prescription for a target medication during the measurement period and who were dispensed a concurrent prescription for a precipitant medication. National Quality Measures Clearinghouse",
      "href": "https://qualitymeasures.ahrq.gov/summaries/summary/47511/drugdrug-interactions-percentage-of-patients-who-received-a-prescription-for-a-target-medication-during-the-measurement-period-and-who-were-dispensed-a-concurrent-prescription-for-a-precipitant-medication?q=drugdrug+interactions"},

      "olvey-2010": {
      "authors": [
      "E. Olvey",
      "S. Clauschee",
      "D. Malone"],
      "title": "Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia",
      "publisher": "Clinical Pharmacology and Therapeutics",
      "pages": "48-51",
      "date": "Jan 2010",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/19890252"},

      "ohdsi-atlas": {
      "authors": ["OHDSI"],
      "title": "OHDSI - Atlas: is an open source software tool for researchers to conduct scientific analyses on standardized observational data",
      "publisher": "Observational Health Data Sciences and Informatics",
      "href": "https://github.com/OHDSI/Atlas"},

      "ohdsi-heracles": {
      "authors": ["OHDSI"],
      "title": "OHDSI - Heracles",
      "publisher": "Observational Health Data Sciences and Informatics",
      "href": "http://www.ohdsi.org/web/wiki/doku.php?id=documentation:software:heracles"},

      "payne-2015": {
      "authors": [
      "Thomas Payne",
      "Lisa Hines",
      "Raymond Chan",
      "Seth Hartman",
      "Joan Kapusnik-Uner",
      "Alissa Russ",
      "Bruce Chaffee",
      "Christian Hartman",
      "Victoria Tamis",
      "Brian Galbreth",
      "Peter Glassman",
      "Shobha Phansalkar",
      "Heleen Sijs",
      "Sheila Gephart",
      "Gordon Mann",
      "Howard Strasberg",
      "Amy Grizzle",
      "Mary Brown",
      "Gilad Kuperman",
      "Chris Steiner",
      "Amanda Sullins",
      "Hugh Ryan",
      "Michael Wittie",
      "Daniel Malone"],
      "title": "Recommendations to improve the usability of drug-drug interaction clinical decision support alerts",
      "publisher": "Journal of the American Medical Informatics Association: JAMIA",
      "pages": "1243-1250",
      "date": "Nov 2015",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/25829460"},

      "pfistermeister-2014": {
      "authors": [
      "B. Pfistermeister",
      "A. SaB",
      "M. Criegee-Rieck",
      "T. Burkle",
      "M. Fromm",
      "R. Maas"],
      "title": "Inconsistencies and misleading information in officially approved prescribing information from three major drug markets",
      "publisher": "Clinical Pharmacology and Therapeutics",
      "pages": "616-624",
      "date": "Nov 2014",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/25062063"},

      "rekic-2017": {
      "authors": [
      "Dinko Rekic",
      "Kellie Reynolds",
      "Ping Zhao",
      "Lei Zhang",
      "Kenta Yoshida",
      "Madhav Sachar",
      "Micheline Piquette', u'Miller",
      "Shiew-Mei Huang",
      "Issam Zineh"],
      "title": "Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access",
      "publisher": "Journal of Pharmaceutical Sciences",
      "pages": "2214-2218",
      "date": "Sep 2017",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/28435142"},

      "loinc-about": {
      "authors": ["LOINC"],
      "title": "LOINC - About",
      "href": "https://loinc.org/about/"},

      "riedmann-2011": {
      "authors": [
      "Daniel Riedmann",
      "Martin Jung",
      "Werner Hackl",
      "Elske Ammenwerth"],
      "title": "How to improve the delivery of medication alerts within computerized physician order entry systems: an international Delphi study",
      "publisher": "Journal of the American Medical Informatics Association: JAMIA",
      "pages": "760-766",
      "date": "2011 Nov-Dec",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/21697293"},

      "ridgely-2012": {
      "authors": [
      "M. Ridgely",
      "Michael Greenberg"],
      "title": "Too Many Alerts, Too Much Liability: Sorting through the Malpractice Implications of Drug-Drug Interaction Clinical Decision Support Clinical Support Systems for Drug-Drug Interactions: Implementing Effective Systems, Limiting Malpractice Liability",
      "publisher": "Saint Louis University Journal of Health Law & Policy",
      "pages": "257-296",
      "date": "2011-2012",
      "href": "http://heinonline.org/HOL/Page?handle=hein.journals/sljhlp5&collection=journals&id=271&startid=&endid=310"},

      "robertson-2007": {
      "authors": [
      "Sarah Robertson",
      "Scott Penzak"],
      "title": "CHAPTER 15 - Drug Interactions",
      "publisher": "Academic Press",
      "pages": "229-247",
      "date": "2007",
      "href": "https://www.sciencedirect.com/science/article/pii/B9780123694171500559"},

      "romagnoli-2017": {
      "authors": [
      "Katrina Romagnoli",
      "Scott Nelson",
      "Lisa Hines",
      "Philip Empey",
      "Richard Boyce",
      "Harry Hochheiser"],
      "title": "Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis of literature review and interviews",
      "publisher": "BMC medical informatics and decision making",
      "pages": "21",
      "date": "February 2017",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/28228132"},

      "rosko-2017": {
  	  "authors": [
      "Samuel C. Rosko",
  	  "Philip Hansten",
  	  "John R. Horn", 
  	  "Daniel C. Malone", 
  	  "Andrew Romero", 
  	  "Richard D. Boyce"],
      "title": "Toward shareable individualized drug interaction alerts.",
  	  "publisher": "AMIA Summit on Clinical Research Informatics",
  	  "date": "Mar 2017"},

      "saverno-2011": {
      "authors": [
      "Kim Saverno",
      "Lisa Hines",
      "Terri Warholak",
      "Amy Grizzle",
      "Lauren Babits",
      "Courtney Clark",
      "Ann Taylor",
      "Daniel Malone"],
      "title": "Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions",
      "publisher": "Journal of the American Medical Informatics Association: JAMIA",
      "pages": "32-37",
      "date": "2011 Jan-Feb",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/21131607"},

      "scheife-2015": {
      "authors": [
      "Richard Scheife",
      "Lisa Hines",
      "Richard Boyce",
      "Sophie Chung",
      "Jeremiah Momper",
      "Christine Sommer",
      "Darrell Abernethy",
      "John Horn",
      "Stephen Sklar",
      "Samantha Wong",
      "Gretchen Jones",
      "Mary Brown",
      "Amy Grizzle",
      "Susan Comes",
      "Tricia Wilkins",
      "Clarissa Borst",
      "Michael Wittie",
      "Daniel Malone"],
      "title": "Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support",
      "publisher": "Drug Safety",
      "pages": "197-206",
      "date": "Feb 2015",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/25556085"},

      "tamblyn-2012": {
      "authors": [
      "Robyn Tamblyn",
      "Tewodros Eguale",
      "David Buckeridge",
      "Allen Huang",
      "James Hanley",
      "Kristen Reidel",
      "Sherry Shi",
      "Nancy Winslade"],
      "title": "The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial",
      "publisher": "Journal of the American Medical Informatics Association: JAMIA",
      "pages": "635-643",
      "date": "2012 Jul-Aug",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/22246963"},

      "tilson-2016": {
      "authors": [
      "Hugh Tilson",
      "Lisa Hines",
      "Gerald McEvoy",
      "David Weinstein",
      "Philip Hansten",
      "Karl Matuszewski",
      "Marianne Comte",
      "Stefanie Higby-Baker",
      "Joseph Hanlon",
      "Lynn Pezzullo",
      "Kathleen Vieson",
      "Amy Helwig",
      "Shiew-Mei Huang",
      "Anthony Perre",
      "David Bates",
      "John Poikonen",
      "Michael Wittie",
      "Amy Grizzle",
      "Mary Brown",
      "Daniel Malone"],
      "title": "Recommendations for selecting drug-drug interactions for clinical decision support",
      "publisher": "American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists",
      "pages": "576-585",
      "date": "Apr 15, 2016",
      "href": "http://www.ncbi.nlm.nih.gov/pubmed/27045070"},

      "fda-cfr-21-5": {
      "authors": ["FDA"],
      "title": "CFR - Code of Federal Regulations Title 21, Volume 5",
      "href": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32"},

      "usdhhs-2017": {
      "authors": [
      "U.S. Department of Health and Human Services",
      "Food and Drug Administration",
      "Center for Drug Evaluation and Research (CDER)"],
	  "title": "Clinical Drug Interaction Studies — Study Design, Data Analysis, and Clinical Implications",
	  "pages": "32",
	  "date": "Oct 2017",
	  "href": "https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf"},

      "utecht-2017": {
      "authors": [
      "Joseph Utecht",
      "Mathias Brochhausen",
      "John Judkins",
      "Jodi Schneider",
      "Richard Boyce"],
      "title": "Formalizing Evidence Type Definitions for Drug-Drug Interaction Studies to Improve Evidence Base Curation",
      "publisher": "Studies in Health Technology and Informatics",
      "pages": "960-964",
      "date": "2017",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/29295242"},

      "van-der-sijs-2006": {
      "authors": [
      "Heleen Van Der Sijs",
      "Jos Aarts",
      "Arnold Vulto",
      "Marc Berg"],
      "title": "Overriding of drug safety alerts in computerized physician order entry",
      "publisher": "Journal of the American Medical Informatics Association: JAMIA",
      "pages": "138-147",
      "date": "2006 Mar-Apr",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/16357358"},

      "wang-2010": {
      "authors": [
      "Lorraine Wang",
      "Maple Wong",
      "James Lightwood",
      "Christine Cheng"],
      "title": "Black box warning contraindicated comedications: concordance among three major drug interaction screening programs",
      "publisher": "The Annals of Pharmacotherapy",
      "pages": "28-34",
      "date": "Jan 2010",
      "href": "https://www.ncbi.nlm.nih.gov/pubmed/20040698"},

      "who-umc-glossary": {
      "authors": ["World Health Organization"],
      "title": "UMC - Glossary",
      "date": "2017",
      "href": "https://www.who-umc.org/global-pharmacovigilance/global-pharmacovigilance/glossary/"},

      "cms-2013": {
      "authors": ["CMS"],
      "title": "Eligible Professional Meaningful Use Core Measures, Measure 2 of 15",
      "pages": "2",
      "date": "2013",
      "href": "http://www.opendental.com/manual/EHR%202011/2%20Drug%20Interaction%20Checks%202012-07%2027.pdf"},

      "usdhhs-2011": {
      "authors": ["U.S. Department of Health and Human Services"],
      "title": "Guidance for Industry - Providing Regulatory Submissions in Electronic Format - Content of Labeling",
      "pages": "8",
      "href": "https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072331.pdf",
      "date":"2011"},

      "ohdsi-study-designer": {
      "authors": ["OHDSI"],
      "title": "Study designer track: Deep dive into cohort study design using ATLAS",
      "href": "https://www.ohdsi.org/wp-content/uploads/2016/09/PLP-Study-Designer-Track.pdf"},

      "osheroff-cds": {
      "authors": [
      "Jerry Osheroff ",
      "Eric Pifer ",
      "Jonathan Teich ",
      "Dean Sittig ",
      "Robert Jenders "],
      "title": "Section 2 - Overview of CDS Five Rights | AHRQ National Resource Center; Health Information Technology: Best Practices Transforming Quality, Safety, and Efficiency",
      "href": "https://healthit.ahrq.gov/ahrq-funded-projects/current-health-it-priorities/clinical-decision-support-cds/chapter-1-approaching-clinical-decision/section-2-overview-cds-five-rights"},

      "sprycel-2015": {
      "title": "Sprycel",
      "publisher": "Bristol-Myers Squibb Company, Princeton, NJ",
      "date": "2015"},

 	  "bosulif-2015": {
      "title": "Bosulif",
      "publisher": "Pfizer Labs, New York, NY",
      "date": "2015"},

 	  "tasigna-2015": {
      "title": "Tasigna",
      "publisher": "Novartis, East Hanover, NJ",
      "date": "2015"},

 	  "yin-2012": {
      "authors": [
      "Ophelia Q.P. Yin",
      "Frank J. Giles",
      "Michele Baccarani",
      "Philipp Le Coutre",
      "Ovidiu Chiparus",
      "Neil Gallagher",
      "Giuseppe Saglio",
      "Timothy P. Hughes",
      "Andreas Hochhaus",
      "Hagop M. Kantarjian",
      "Richard A. Larson"],
      "title": "Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia",
      "publisher": "Cancer Chemotherapy and Pharmacology",
      "pages": "345-350",
      "date": "2012",
  	  "href": "https://www.ncbi.nlm.nih.gov/pubmed/22623211"},
 	  "iclusig-2016": {
      "title": "Iclusig",
      "publisher": "ARIAD Pharmaceuticals, Inc., Cambridge, MA",
      "date": "2016"},

 	  "egorin-2009": {
      "authors": [
      "Merrill J. Egorin",
      "Dhvani D. Shah",
      "Susan M. Christner",
      "Mara A. Yerk",
      "Kristin A. Komazec",
      "Leonard R. Appleman",
      "Robert L. Redner",
      "Brian M. Miller",
      "Jan H. Beumer"],
      "title": "Effect of a proton pump inhibitor on the pharmacokinetics of imatinib",
      "publisher": "British Journal of Clinical Pharmacology",
      "pages": "370-374",
      "date": "2009",
  	  "href": "https://www.ncbi.nlm.nih.gov/pubmed/19740393"}

      },
      specStatus: "CG-DRAFT",
      edDraftURI: "https://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/w3c-ddi/index.html",
      editors: [
      {
      name: "Richard D. Boyce",
      url: "www.dbmi.pitt.edu/person/richard-boyce-phd",
      company: "Department of Biomedical Informatics, University of Pittsburgh, USA"
      },
      {
      name: "Ratnesh Sahay",
      company: "Insight Center for Data Analytics, NUI Galway, Ireland"
      },
      {
      name: "Serkan Ayvaz",
      company: "Department of Software Engineering, Bahcesehir University, Istanbul, Turkey"
      },
      {
      name: "Harry Hochheiser",
      url: "www.dbmi.pitt.edu/person/harry-hochheiser-phd",
      company: "Department of Biomedical Informatics, University of Pittsburgh, USA"
      },
      {
      name: "Elizabeth A. Garcia",
      company: "School of Pharmacy, University of Pittsburgh, USA"
      },
      {
      name: "Michel Dumontier",
      company: "Institute of Data Science, Maastricht University, Netherlands"
      }],
      authors: [
      {
      name: "Brian LeBaron",
      company: "Southeast Louisiana Veterans Health Care System, USA"
      },
      {
      name: "Brian Hocum",
      company: "Genelex, Seattle, USA"
      },
      {
      name: "Daniel C. Malone",
      company: "College of Pharmacy, University of Arizona, USA"
      },
      {
      name: "Evan Draper",
      company: "Pharmacy Services, Mayo Clinic, USA"
      },
      {
      name: "Jodi Schneider",
      company: "University of Illinois at Urbana-Champaign, USA"
      },
      {
      name: "Sam Habiel",
      company: "Open Source Electronic Health Records Alliance (OSEHRA), USA"
      },
      {
      name: "John Horn",
      company: "School of Pharmacy, University of Washington, USA"
      },
      {
      name: "Juan M. Banda",
      company: "Stanford University, USA"
      },
      {
      name: "Katrina Romagnoli",
      company: "University of Pittsburgh Medical Center, USA"
      },
      {
      name: "Lorne Walker",
      company: "University of Pittsburgh Medical Center, USA"
      },
      {
      name: "Louisa (Yu) Zhang",
      company: "University of Pittsburgh, USA"
      },
      {
      name: "Maria Herrero-Zazo",
      company: "King’s College London, United Kingdom "
      },
      {
      name: "Mathias Brochhausen",
      company: "University of Arkansas for Medical Sciences, USA"
      },
      {
      name: "Oktie Hassanzadeh",
      company: "IBM Research, USA"
      },
      {
      name: "Oya Beyan",
      company: "Fraunhofer FIT, Germany"
      },
      {
      name: "Øystein Nytrø",
      company: "Norwegian University of Science and Technology, Norway"
      },
      {
      name: "Thomas Reese",
      company: "University of Utah, USA"
      },
      {
      name: "Xia Jing",
      company: "Ohio University, USA"
      }],
      github: "https://github.com/W3C-HCLS/w3c-ddi",
      shortName: "MPIO",
      wg: "Semantic Web in Health Care and Life Sciences Community Group",
      wgPublicList: "public-hclscg",
      wgURI: "https://www.w3.org/community/hclscg/"
      };
    </script>
    <style>
      body {text-wrap: normal}
      table, th, td{border: 1px solid black;
      margin: 25px
      }
      th, td {padding: 10px}
    </style>
  </head>
  <body>
    <section id='abstract'>
      <p>

Ensuring medication therapy occurs safely and to the maximum benefit
for any given patient is of great interest to clinicians
[[institute-medicine-2006]]. One possible threat to patient safety comes
from exposure to two or more drugs that are known to interact (i.e.,
potential drug-drug interactions or PDDIs), and could therefore lead
to a clinically observable effect on the patient (i.e., an actual
drug-drug interaction).  New information regarding
PDDIs is published every day in primary sources such as drug product
labeling and the scientific literature. However, there are currently
no broadly accepted standards to guide these experts in the
organization and presentation of PDDI information for clinical decision support. These shortcomings suggest
the need for harmonized approaches for documenting and sharing PDDI
information. The purpose of this Community Group Note is to
provide a technical and user-centered foundation for a minimum
information model for PDDI information. The resulting common
representation of PDDI summaries would facilitate curation and
information exchange. Downstream applications would process these
representations into forms amenable for clinical decision support,
drug product label enhancement, cohort identification, and other
pharmacovigilance activities.  





      </p>
    </section>
    <section id='sotd'>
      This draft is currently open for editing suggestions by all interested stakeholders.
</p>
<p>
  This document is governed by the <a href="https://www.w3.org/community/reports/reqs/">W3C  requirements of the Community and Business Group Process related to deliverables</a>.
</p>
</section>
<section>
  <h2>Introduction</h2>
  <p>
    Ensuring medication therapy occurs safely and to the maximum benefit for of any given patient is of great
    interest to clinicians [[institute-medicine-2006]]. One possible threat to patient safety comes from exposure
    to two or more drugs that are known to interact (i.e., potential drug-drug interactions or PDDIs), and could therefore
    lead to a clinically observable effect on the patient (i.e., an actual drug-drug interaction). While the effects
    that may occur due to exposure to some PDDIs can benefit patients (e.g., some HIV therapies use a low-dose of ritonavir
    to increase plasma concentrations of co-administered protease inhibitors by inhibiting their metabolism), PDDIs are
    more often a patient safety concern. Clinically important events that are attributable to PDDI exposure occur in
    5.3% - 14.3% of inpatients, and are responsible for up to 231,000 emergency department visits that occur each year in
    the United States alone [[magro-2012]][[cdc-faststats]]. A recent systematic review and meta-analysis of 13 studies conducted
    on 3 continents found the median rate of PDDI associated hospital admissions to be 22.2%
    (interquartile range 16.6 - 36.0%) [[dechanont-2014]]. The potential for harm from PDDIs is an international concern reflected in 
    guidance documents of regulatory agencies around the world [[rekic-2017]][[european-medicines-2012]][[usdhhs-2017]]. Moreover, in the United States, PDDI alerting is a criteria included in the so-called Meaningful Use criteria
    for Electronic Health Records [[cms-2013]][[ridgely-2012]]), and population-based strategies for tracking exposure
    are promoted by organizations such as the Pharmacy Quality Alliance [[ahrq-drug-drug]].
  </p>
  <p>
    Clinicians often face barriers to the effective and appropriate management of PDDI exposures [[nabovati-2017]].
    Barriers include PDDI alerts with poor specificity and incomplete personal PDDI knowledge [[abarca-2004]][[van-der-sijs-2006]]
    . An awareness of the need for PDDI decision support prompts clinicians to use various drug
    knowledge resources including print or online drug information references, drug interaction checking tools, and alerting systems.
    Unfortunately, poor specificity leads clinicians to be overwhelmed by PDDI information that is “difficult to retrieve, sort and
    digest into clinical decision making” [[bottiger-2009]]. PDDI alerts are often  criticized for “over-alerting” that
    obfuscates the most important information, hinders the usability of the decision support system, and leads to alert fatigue
    and clinician dissatisfaction [[bottiger-2009]][[payne-2015]]. Moreover, while many compilations of
    PDDI evidence exist to help improve prescriber and pharmacist knowledge, they are not concordant in their coverage,
    accuracy, and agreement [[wang-2010]][[saverno-2011]][[ayvaz-2015]][[fung-2017]]. Together, these
    shortcomings suggest the need for harmonized approaches for documenting and sharing PDDI information.
  </p>
  <section>
    <h2>Need, envisioned workflow, and high-level requirements</h2>
    <p>New information regarding PDDIs is published every day in primary sources such as drug product labeling and the scientific
      literature. A PubMed search for publications indexed with the Medical Subject Headings keyword “Drug interactions” shows an
      average of 3,970 publications per year from 2000 through 2016. This suggests that the body of evidence about PDDIs is
      overwhelming and dynamic. As it is impossible for clinicians to keep up with the PDDI evidence base, drug
      experts generate summaries of PDDI evidence from primary sources. These summaries bring PDDI knowledge to clinicians
      in the form of published drug information compendium, clinical decision support rules, and interaction checking applications.
      <strong>However, there are currently no broadly accepted standards to guide these experts in the organization and presentation of PDDI
        information that would be most effective for clinical decision support.</strong>
    </p>

    <p><a href="#PDDI-MI-APPLICATIONS"></a> provides an overview of
      the roles envisioned for a PDDI minimal information model.  Drug
      experts would generate summaries of PDDI evidence from primary
      sources using the information elements from the PDDI minimal
      information model. The information elements would cover the
      minimum set of information required for the effective clinical
      management of PDDI exposure. The resulting common representation
      of PDDI summaries would facilitate curation and information
      exchange. Downstream applications would process these
      representations into forms amenable for clinical decision
      support, drug product label enhancement, cohort identification,
      and other pharmacovigilance activities. To achieve the
      envisioned roles, the minimal information model must be flexible
      and computable. Where possible, model elements should draw upon
      accepted biomedical taxonomies and ontologies to represent
      medications, diagnoses, and descriptions of potential adverse
      reactions. Preferring the use of ontologies over free-text
      descriptions will reduce ambiguity associated with free-text,
      thus supporting comparison and computational
      analyses. Representations in commonly-used formats (JSON,XML/RDF
      ,etc.) will support ease of construction and parsing of models,
      particularly through shared libraries and APIs.
      </p>

    <figure id="PDDI-MI-APPLICATIONS">
      <img src="Presentations/images/info-model-value-proposition.png"
      width"1152" height="864">
      <figcaption>An overview of the role envisioned for a PDDI minimal information model. </figcaption>
    </figure>

    <p>The purpose of this Community Group Note is to provide a
      technical and user-centered foundation for a minimum
      information model for PDDI information. The principal
      contributions include:
      <ol>
	      
	<li>definitions for the model's core information items,
	  examples of using these definitions to represent two PDDIs,
	  and a set of additional PDDIs selected as case studies for
	  future work on the information model;</li>
	<li>clarification on the intended users of the information model
	  along with use stories and specific information needs; and</li>
	<li>a statement on the appropriate scope of knowledge representation
	  for the information model.</li>
      </ol>

    The focus of this document is definition of the model, not
    representation. Although this document provides preliminary XML
    examples of the use of the model to represent PDDI information
    (see <a href="#appendix-xml"></a>), detailed representational
    issues are not discussed in this document. Planned future efforts
    will address these questions. 
    </p>
  </section>
</section>

<section id ="the-model">
 <h2>The Minimum Information Model</h2>

<section id="user-centered-def">
  <h2>Definitions of Core Information Items</h2>
  <p>
    The minimum information model contains a total of 10 core
    information items. Definitions are given below; descriptions of
    considerations informing the     definitions of these term can be
    found at (<a target="new"
    href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/User-centered-definitions"> 
    https://github.com/W3C-HCLS/w3c-ddi/tree/master/User-centered-definitions</a>): 
  </p>
  <ul>
    <li><dfn>Drugs Involved</dfn> (<a target="new"
    href="http://purl.obolibrary.org/obo/MPIO_ABCDEFG"><span style="color:red">http://purl.obolibrary.org/obo/MPIO_ABCDEFG<span></A>):
    The drugs considered to be possible participants in a potential
    drug-drug interactions. Drugs may be specified as drug classses
    (such as NSAIDs), as specific chemicals, as products, or in any other
    appropriate granularity.</LI>

    <li><dfn>Clinical Consequences</dfn> (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000002">http://purl.obolibrary.org/obo/MPIO_0000002</a>):
      Changes in patient health status from baseline that can be observed or measured by a
      clinician or reported by a patient.</li>

    <li> <dfn>Seriousness</dfn> (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000009">http://purl.obolibrary.org/obo/MPIO_0000009</a>):
      As defined by he World Health Organization an event is serious
      if it &quot;results in death; requires hospitalization or
      extension of hospital stay; results in persistent or significant
      disability or incapacity; is life-threatening&quot;
      [[who-umc-glossary]]. Seriousness may determine the type and speed
      of clinician intervention.</li>
    <li><dfn>Severity</dfn> (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000010">http://purl.obolibrary.org/obo/MPIO_0000010</a>):
      The intensity of a drug-drug interaction clinical
      consequence.</li>

   <li><dfn>Mechanism of Interaction</dfn> (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000005">http://purl.obolibrary.org/obo/MPIO_0000005</a>):
      The process(es) by which a drug-drug interaction with clinical
      consequence occurs.</li>

    <li><dfn>Recommended Action</dfn> (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000008">http://purl.obolibrary.org/obo/MPIO_0000008</a>):
      An evidence-based strategy to mitigate the potential clinical consequences of a drug-drug interaction such as a drug change, adjust drug dose, and monitor lab values.</li>

    <li><dfn>Contextual information/modifying factors</dfn>
      (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000000">http://purl.obolibrary.org/obo/MPIO_0000000</a>):
      Factors such as patient age, patient health conditions, route of administration, product formulation, drug dose, pharmacogenetics,
      or concurrent medications that might alter the risk of a drug-drug interaction clinical consequence or its seriousness. </li>
    <li><dfn>Evidence for a Suspected Drug-Drug Interaction</dfn> (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000004">http://purl.obolibrary.org/obo/MPIO_0000004</a>):
      The support for or refutation of a drug-drug interaction in humans, potentially including data resulting
      from clinical studies, clinical observation, physiological experiments, or extrapolation based
      on drug-drug interaction mechanisms.</li>
 
    <li><dfn>Frequency of Exposure to the PDDI</dfn> (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000007">http://purl.obolibrary.org/obo/MPIO_0000007</a>):
      When available, the number of individuals within a cohort that are exposed to a drug-drug interaction over a specified time
      period divided by the total number of patients in the cohort.</li>
    <li><dfn>Frequency of Harm for persons who have been exposed to the PDDI</dfn> (<a target="new" href="http://purl.obolibrary.org/obo/MPIO_0000006">http://purl.obolibrary.org/obo/MPIO_0000006</a> ):
      When available, the number of individuals within a cohort that experience a clinical consequence of a drug-drug interaction clinical consequence divided by the total number of patients co-exposed to the drugs involved.</li>


  </ul>
 <p>
These core information elements are consistent with the results of a separate international Delphi study on how
      to improve the delivery of medication alerts within computerized physician order entry systems [[riedmann-2011]].
      This suggested list of core information elements includes some that are present in one or more of the 15 PDDI conceptual
      models analyzed in a recent comprehensive review by Herrero-Zazo, Segura-Bedmar, and Martínez [[herrero-zazo-2016]].
      However, there is little commonality across the conceptual models on those elements that are included and no single
      conceptual model covers all 9 of the information elements. For example, the mechanism of the interaction and clinical
      consequences were present in multiple models but at different levels of granularity. Other information elements, such
      as frequency of exposure and frequency of harm are not present in any of the 15 sources. Even PDDI knowledge bases that
      are strongly clinically-oriented (as opposed to  knowledge bases oriented toward use in bioinformatics or drug development)
      use considerably different information elements. For example, the National Drug File - Reference Terminology (NDF-RT)
      produced by the U.S. Department of Veterans Affairs [[olvey-2010]] includes detailed information about pharmacokinetic
      mechanisms but does not discuss clinical consequences. In contrast, the system reported by Mille, Degoulet, and Jaulent
      [[mille-2007]] provided details on the clinical consequences, including risk increasing and mitigating factors,
      but supplied only a limited structure for mechanism.
 </p>

 <p>Although not used by practitioners and clinicians, seriousness is
 an important concept for pharmacovigilance and
 pharmacoepidemiological studies. The adoption of this term aligns
 this effort with definitions adopted by the World Health
 Organization[[who-umc-glossary]], the United States Food and Drug
 Administration [[usdhhs-2011]], and other organizations involved in
 pharmacovigilance efforts.
   </p>
  <p>
    The interested reader can review details on each definition in
    documnets  downloadable from GitHub (<a target="new"
    href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/User-centered-definitions">https://github.com/W3C-HCLS/w3c-ddi/tree/master/User-centered-definitions</a>).
  </p>
  </section>

  <section id="examples">
  <h2>Examples of the use of the minimal information model</h2>
    We provide limited discussion of the definitions in the form of two example
    PDDIs, chosen from a larger set of 14 exemplar potential drug-drug
    interactions examined during the develompent of the minimal
    information model (see <a href="#decision-trees"></a>).
  <section id="ex-warfarin-nsaids">
    <h2>Applying the Minimal Information Model definitions to the PDDI between warfarin
      and non-steroidal anti-inflammatory drugs (NSAIDs)</h2>
    <p>
      We illustrate here the application of the Minimum Information Model definitions to representing the PDDI involving warfarin
      and non-steroidal anti-inflammatory drugs (NSAIDs). Details of
      the development process can be found
      in <a href="#warfarin-nsaids-dt"></a>. Note that the capitalized keywords (MUST, MUST NOT, REQUIRED, SHALL, SHALL NOT, SHOULD, SHOULD NOT, RECOMMENDED, MAY, AND OPTIONAL) are defined in RFC 2119 [[RFC2119]]. 
    </p>

    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Drugs involved</strong>: <a href="#warfarins">Warfarin</a> and <a href="#NSAIDS-drugs">non-steroidal anti-inflammatory drugs (NSAIDs)</a> </td>
      </tr>
      <tr>
	<td>
	  <strong>Comment:</strong> The drugs involved in a PDDI MUST be explicitly stated. To support a computable representation of the PDDI, the drugs involved SHOULD be listed as sets of terms from a terminology such as <a href="https://www.nlm.nih.gov/research/umls/rxnorm/" target="new">RxNorm</a> or the <a href="https://www.whocc.no/atc/structure_and_principles/" target="new">Anatomical Therapeutic Chemical Classification System (ATC)</a>. Such so called <i>value sets</i> MAY be referenced by a URI to a public repository such as the <a href="https://vsac.nlm.nih.gov/" target="new">Value Set Authority Center</a> that is maintained by the <a href="https://www.nlm.nih.gov/" target="new">United States National Library of Medicine</a>.</td> 
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><a>Clinical Consequences</a>: Increased risk of bleeding including <a href="#gi-bleeding">gastrointestinal bleeding</a>,  <a href="#icran-hemm">intracranial hemorrhage</a>,  and <a href="#cereb-hemm">cerebral hemorrhage</a></td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> The clinical consequences associated with a PDDI MUST be reported if known. Clinical consequences SHOULD refer health outcomes as specifically as possible. To support a computable representation of the PDDI, clinical consequences SHOULD be represented as one or more sets of terms from a terminology such as <a href="http://www.who.int/classifications/icd/en/" target="new">ICD-10</a> or <a href="https://www.snomed.org/snomed-ct" target="new">SNOMED-CT</a>. Such so called <i>value sets</i> MAY be referenced by a URI to a public repository such as the <a href="https://vsac.nlm.nih.gov/" target="new">Value Set Authority Center</a> that is maintained by the <a href="https://www.nlm.nih.gov/" target="new">United States National Library of Medicine</a>.</td> 
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><a>Seriousness</a>: Bleeding is a serious potential clinical consequence because it can result in death, life-threatening hospitalization, and disability. </td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> A PDDI clinical consequence MUST be noted as <i>serious</i> if it can result in death, life-threatening hospitalization, congenital anomaly, disability, or if it requires intervention to prevent permanent impairment or damage.</td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><a>Severity</a>: While bleeding is a serious potential clinical consequence, severity can vary from easily tolerated to incapacitating </td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> The severity of a PDDI clinical consequence MUST be reported if known. The severity of a PDDI clinical consequence MUST be noted using non-ambiguous terms or phrases. Any of the existing terminologies for adverse event severity, such as Common Terminology Criteria for Adverse Event (CTCAE) [[ctcae-wiki]], MAY be used for describing a PDDI clinical consequence.</td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><a>Mechanism of Interaction</a>: <a href="#NSAIDS-drugs">Non-steroidal anti-inflammatory drugs (NSAIDs)</a> have
          antiplatelet effects which increase the bleeding risk when combined with oral anticoagulants such as
          <a href="#warfarins">warfarin</a>. The antiplatelet effect of NSAIDs lasts only as long as the NSAID is present in the circulation,
          unlike aspirin’s antiplatelet effect, which lasts for up to 2 weeks after aspirin is discontinued. NSAIDs also
          can cause peptic ulcers and most of the evidence for increased bleeding risk with NSAIDs plus warfarin is due to
          upper gastrointestinal bleeding (UGIB).</td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> The mechanism of a PDDI MUST be reported if known. The description SHOULD be written for a clinician audience and include details that help the clinician decide what course of management action to take. To reduce ambiguity, the description MAY refer to specific drugs or health conditions using codes from terminologies. </td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><a>Recommended Action</a>: If the NSAID is being used as an analgesic or antipyretic,
          it would be prudent to use an alternative such as acetaminophen. In some people, acetaminophen can
          increase the anticoagulant effect of warfarin, so monitor the INR if acetaminophen is used in doses
          over 2 g/day for a few days. For more severe pain consider short-term opioids in place of the NSAID.</td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> Any recommended actions that apply to all patient exposures SHOULD be stated using clear and concise language. The recommended action statement SHOULD also provide citations to <a>evidence for a suspected drug-drug interaction</a> (not provided in this example). Recommendations that depend on <a>contextual information/modifying factors</a> SHOULD be mentioned separately to support context-specific presentation of such information.</td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><a>Contextual information/modifying factors</a>:
          <ol>
            <li>The <a href="#NSAIDS-drugs">NSAIDs</a> is <a href="#topical-diclof">topical diclofenac</a></li>
            <ul>
              <li><strong>Recommended Action:</strong> No special precautions</li>
              <li><strong>Evidence for a Suspected Drug-Drug Interaction:</strong> <a href="#topical-diclof">Topical diclofenac</a> has relatively
		low systemic absorption; in one study a topical gel (16 g/day) produced about 6% of
		the absorption seen with systemic administration of 150 mg/day. A higher than recommended
		dose of topical gel (48 g/day) produced 20% of a systemic dose of diclofenac.</li>
            </ul>
            <li>The NSAID is NOT <a href="#topical-diclof">topical diclofenac</a> but the patient is concomitantly taking a
              <a href="#proton-pump-inhibitor">proton pump inhibitor</a> or <a href="#misoprostol">misoprostol</a></li>
            <ul>
              <li><strong>Recommended Action:</strong> Assess risk and take action if necessary</li>
              <li><strong>Evidence for a Suspected Drug-Drug Interaction:</strong> <a href="#proton-pump-inhibitor">Proton pump inhibitors</a> and <a href="#misoprostol">misoprostol</a> may reduce the risk of UGIB in patients receiving NSAIDs and warfarin. </li>
            </ul>
            <li>The NSAID is NOT <a href="#topical-diclof">topical diclofenac</a>, the patient is NOT concomitantly taking a <a href="#proton-pump-inhibitor">proton pump inhibitor</a> or <a href="#misoprostol">misoprostol</a>, and the patient has one or more of the following risk factors:</li>
            <ul>
              <li>History of <a href="#gi-bleeding">upper gastrointestinal bleeding (UGIB) or peptic ulcer</a> or age > 65 years old</li>
              <ul>
		<li><strong>Recommended Action:</strong> Use only if benefit outweighs risk</li>
		<li><strong>Evidence for a Suspected Drug-Drug Interaction:</strong> Patients with a
                  history of UGIB or peptic ulcer may have an increased risk of UGIB from this interaction.
                  The extent to which older age is an independent risk factor for UGIB due to these interactions
                  is not firmly established, but UGIB in general is known to increase with age.</li>
              </ul>
              <li>Concomitantly taking <a href="#systemic-cortico">systemic corticosteroids</a>, <a href="#aldosterone-antagonists">aldosterone antagonists</a>, or high dose or multiple <a href="#NSAIDS-drugs">NSAIDs</a></li>
              <ul>
		<li><strong>Recommended Action:</strong> Use only if benefit outweighs risk</li>
		<li><strong>Evidence for a Suspected Drug-Drug Interaction:</strong> Both corticosteroids
                  and aldosterone antagonists have been shown to substantially increase the risk of UGIB in
                  patients on NSAIDs, with relative risks of 12.8 and 11 respectively compared
                  to a risk of 4.3 with NSAIDs alone [[masclee-2014]]</li>
              </ul>
            </ul>
          </ol>
	</td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> <a>Contextual information/modifying factors</a> are necessary for alerts that
          are both sensitive and specific. Like clinical consequences, each known factor SHOULD be
          stated as specifically as possible. The factors SHOULD be amenable to implementation as executable
          logic using value sets from clinical terminologies such as <a href="https://www.nlm.nih.gov/research/umls/rxnorm/" target="new">RxNorm</a>, the
	  <a href="https://www.whocc.no/atc/structure_and_principles/" target="new">Anatomical Therapeutic Chemical Classification System (ATC)</a>, <a href="http://www.who.int/classifications/icd/en/" target="new">ICD-10</a>, and <a href="https://www.snomed.org/snomed-ct" target="new">SNOMED-CT</a>. As is used in this
          example, each factor SHOULD be related to a specific <a>recommended action</a> that is supported by the <a>evidence for a suspected drug-drug interaction</a></td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Frequency of Exposure to the PDDI:</strong> Unknown</td>
      </tr>
      <tr>		      
	<td><strong>Comment:</strong> Frequency of exposure and frequency of harm information is
          rarely available but can help a clinician assess the risk/benefit trade-off of exposure to PDDI. Such information SHOULD be provided if available. </td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Frequency of Harm for persons who have been exposed to the PDDI:</strong> Unknown</td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> Frequency of exposure and frequency of harm information is
          rarely available but can help a clinician assess the risk/benefit trade-off of exposure to PDDI. Such information SHOULD be provided if available. </td>
      </tr>
    </table>
  </section>
  <section id="ex-tki-ppi">
    <h2>Applying the Minimal Information Model definitions to the PDDI between BCR-ABL
      Tyrosine Kinase Inhibitors (TKI) + Proton Pump Inhibitors (PPI)</h2>
    <p> Minimal information Model definitions and discussion comments
      (were differing from the previous example) for the  PDDI
      involving  BCR-ABL Tyrosine Kinase Inhibitors (TKIs) + Proton
      Pump Inhibitors (PPIs). 
    </p>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><emph>Drugs involved</emph>: <a href="#TKIs">Tyrosine Kinase Inhibitors (TKIs)</a> and <a href="#proton-pump-inhibitor-atc">Proton Pump Inhibitors (PPIs)</a></td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> Note that in the previous example the drugs involved are specified using RxNorm while this example uses ATC. This is to emphasize that, while the drugs involved SHOULD be listed as sets of terms from a terminology such as <a href="https://www.nlm.nih.gov/research/umls/rxnorm/" target="new">RxNorm</a> or the <a href="https://www.whocc.no/atc/structure_and_principles/" target="new">Anatomical Therapeutic Chemical Classification System (ATC)</a>, the implementer MAY choose any terminology they think appropriate. To promote broader accessibility to PDDI knowledge, it is RECOMMENDED that the chosen terminology be one that is actively maintained and freely accessible to the public.</td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Clinical Consequences:</strong> Decreased efficacy relative to treatment for <a href="#acml">chronic myeloid leukemia</a></td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> Note that in the previous example the clinical consequences involved are specified using <a href="http://www.who.int/classifications/icd/en/" target="new">ICD-10</a> while this example uses <a href="https://www.snomed.org/snomed-ct" target="new">SNOMED-CT</a>. This is to emphasize that, while the clinical consequences  SHOULD be listed as sets of terms from a terminology such as ICD-10 or SNOMED-CT, the implementer MAY choose any terminology they think appropriate. To promote broader accessibility to PDDI knowledge, it is RECOMMENDED that the chosen terminology be one that is actively maintained and freely accessible to the public.</td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Seriousness:</strong> A decrease in chronic myeloid leukemia treatment efficacy is
          a serious potential clinical consequence because it can result in death, life-threatening
          hospitalization, and disability. </td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> A PDDI clinical consequence MUST be noted as <i>serious</i> if it can result in death, life-threatening hospitalization, congenital anomaly, disability, or if it requires intervention to prevent permanent impairment or damage.</td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Severity:</strong> There is no intensity scale relevant to describing a decrease in chronic
          myeloid leukemia treatment efficacy </td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> If there is no relevant description of intensity for the clinical consequence of a given PDDI, this SHOULD be explicitly stated. </td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Mechanism of Interaction:</strong> BCR-ABL Tyrosine Kinase inhibitors demonstrate pH
          dependent absorption for oral administration which may result in decreased efficacy when given
          concomitantly with medications that increase gastric pH.  </td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> The mechanism of a PDDI MUST be reported if known. The description SHOULD be written for a clinician audience and include details that help the clinician decide what course of management action to take. To reduce ambiguity, the description MAY refer to specific drugs or health conditions using codes from terminologies. A limitation of this example is that it refers to 'medications that increase gastric pH' without reference any specific drugs or codes from a drug terminology. </td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Contextual information/modifying factors:</strong></td>
      </tr>
      <tr>
	<td>
          <ul>
            <li>The TKI is <a href="#imatinib">imatinib</a> or <a href="#ponatinib">ponatinib</a></li>
            <ul>
              <li><strong>Recommended Action:</strong> No special precautions</li>
              <li><strong>Evidence for a Suspected Drug-Drug Interaction:</strong> Imatinib and ponatinib AUCs are not appreciably
		decreased by PPI co-administration </li>
              <ul>
		<li>Iclusig [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc. 2016., and </li>
		<li>Egorin MJ, Shah DD, Christner SM, et al. Effect of a proton pump inhibitor on the
                  pharmacokinetics of imatinib. Br J Clin Pharmacol. 2009;68(3):370-374.)</li>
              </ul>
            </ul>
            <li>The TKI is <a href="#nilotinib">nilotinib</a></li>
            <ul>
              <li><strong>Recommended Action:</strong> Assess risk and take action if necessary</li>
              <li><strong>Evidence for a Suspected Drug-Drug Interaction:</strong>Bosutinib and nilotinib AUCs
		are decreased with concomitant PPIs but antacids and H2 antagonists may be considered if
		TKI is given 2 hours before the antacid/H2 antagonist.2,3 However, for nilotinib a retrospective
		study has shown no difference in cytogenetic response rates for patients taking PPIs.</li>
              <ul>
		<li>Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2
                  blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid
                  leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350.</li>
              </ul>
            </ul>
            <li>The TKI is <a href="#bosutinib">bosutinib</a> or <a href="#dasatinib">dasatinib</a></li>
            <ul>
              <li><strong>Recommended Action:</strong> Use only if benefit outweighs risk</li>
              <li><strong>Evidence for a Suspected Drug-Drug Interaction:</strong>Bosutinib and nilotinib
		AUCs are decreased with concomitant PPIs but antacids and H2 antagonists may be considered
		if TKI is given 2 hours before the antacid/H2 antagonist.</li>
              <ul>
		<li>Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015</li>
		<li>Bosulif [package insert]. New York, NY: Pfizer Labs; 2015.</li>
		<li>Tasigna [package insert]. East Hanover, NJ: Novartis; 2015.</li>
              </ul>
            </ul>
          </ul>
	</td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> The same comments about stated in the previous example about the contextual information/modifying factors. As for other information items, reference to coded terms for drugs and other relevant entities SHOULD be used to reduce ambiguity. Notice that this example could be improved because it references coded terms for TKIs but not for antacids and H2 antagonists. The implementer MAY choose any terminologies they think appropriate. To promote broader accessibility to PDDI knowledge, it is RECOMMENDED that the chosen terminologies be one that is actively maintained and freely accessible to the public.</td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Frequency of Exposure to the PDDI:</strong> Unknown</td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> Frequency of exposure and frequency of harm information is
          rarely available but can help a clinician assess the risk/benefit trade-off of exposure to PDDI. Such information SHOULD be provided if available. </td>
      </tr>
    </table>
    <table>
      <tr>
	<td style="background-color: #f4fff2"><strong>Frequency of Harm for persons who have been exposed to the PDDI:</strong> Unknown</td>
      </tr>
      <tr>
	<td><strong>Comment:</strong> Frequency of exposure and frequency of harm information is
          rarely available but can help a clinician assess the risk/benefit trade-off of exposure to PDDI. Such information SHOULD be provided if available. </td>
      </tr>

    </table>
  </section>
</section>
</section>

<section id="justification">
  <h2>Background and use cases</h2>

  <section id="overarching-use-case">
    <h2>The overarching use case for the minimum information model</h2>
    <p>
      The overarching use case for a minimum information model for
      representing PDDI information in a clinical context
      is <strong>to provide a technical foundation for effective PDDI
      clinical decision support</strong>. Unfortunately, existing drug
      information sources systems generally organize information into
      a more or less narrative format includes only some of the core
      PDDI information elements. To illustrate, consider the PDDI
      between oral anticoagulants and non-steroidal anti-inflammatory
      drugs (NSAIDs) reported in the well-curated French Interactions
      médicamenteuses PDDI dataset [[ansm-2016]] shown
      in <a href="#NSAID-Example"></a>.
    </p>
    <figure id="NSAID-Example">
      <img src="W3C-Images/NSAID-Example.png">
      <figcaption>PDDI example from a French compendium</figcaption>
    </figure>
    <p>
      The PDDI narrative shown is structured into short and easy-to-read description and management
      sections. However, much of the information in the proposed minimum information model is either not structured
      or not provided:
    </p>
    <ul>
      <li><em>Drugs Involved</em> - textual, non-standardized, non-coded lists of ingredients that have been
        classified as either NSAIDs or as oral anticoagulants</li>
      <li><em>Clinical consequences</em> - textual, non-standardized, non-coded mention of “hemorrhage” </li>
      <li><em>Frequency of exposure to the PDDI</em> - no mention </li>
      <li><em>Frequency of harm for persons who have been exposed to the PDDI</em> - no mention</li>
      <li><em>Contextual information/modifying factors</em> - no mention</li>
      <li><em>Evidence</em> - no mention</li>
      <li><em>Mechanism of the interaction</em> - textual, non-standardized, mention of gastroduodenal irritation by the NSAID</li>
      <li><em>Recommended actions</em> - avoidance if possible, monitoring otherwise</li>
      <li><em>Seriousness rating</em> - not explicit. However, the statement “not recommended” would suggest a risk of clinically significant consequence</li>
    </ul>
    <p>
      As is evident from the listing above, there are four minimum information items that are not provided in the
      narrative (contextual information, frequency of exposure, frequency of harm, and evidence). Contextual information
      would include drug and patient characteristics factors that might increase or mitigate the risk of harm from exposure
      to the interaction drug pair. Such information often complements, and sometimes is based on , information on the
      frequency information items (frequency of exposure to the PDDI and frequency of harm for exposed persons who have
      been exposed). Together, these information items help to inform the clinician about the risk-benefit trade-off of PDDI
      exposure. In fact, it has been shown that effective clinical decision support that improves patient outcomes can be
      built using such information. For example, Tamblyn et al. found that a novel medication clinical decision support system
      that provided patient-specific risk estimates of injury due to falls reduced fall-related injury by 1.7 injuries per 1000
      patients (95% CI 0.2/1000 to 3.2/1000 p=0.02) [[tamblyn-2012]]. Conversely, when a PDDI summary provides no context
      about risk and no frequency information, only clinical decision support alerts based on  simple exposure to the drug
      combination can be built. This leads to highly sensitive but unspecific alerts and is a primary cause of alert fatigue and
      clinician dissatisfaction  [[van-der-sijs-2006]].
    </p>
    <p>
      Further, the PDDI narrative in <a href="#NSAID-Example"></a>
      provides information without citing supporting evidence.
      Previous community efforts concluded that “providing access to the evidence is a critical component
      of weighing the risks and benefits of co-prescribing drugs that have the potential to result in a drug-drug interaction”
      [[tilson-2016]]. Evidence in supporting PDDIs includes physiological and pharmacological observations from
      clinical studies; mechanistic knowledge derived from pre-clinical and clinical studies; and observational data
      including case reports and various non-randomized studies [[utecht-2017]][[brochhausen-2014]]. Evidence
      may be useful for establishing the existence of an interaction without providing information about the potential
      clinical effect. Other evidence can help to answer questions about the associated clinical effects and their magnitude,
      variability, and estimated frequency [[scheife-2015]]. A PDDI representation should cite specific supporting
      evidence items and provide some acceptable appraisal of the total body of evidence [[tilson-2016]].
    </p>
    <p>
      Unstructured narratives may also fail to provide critical information in computable form suitable for creation
      of personalized decision support presentation. The interaction described above notes that the mechanism of the
      interaction involves gastroduodenal irritation by the NSAID, suggesting gastrointestinal hemorrhage as a possible
      consequence. Such an occurrence would seem unlikely to occur for NSAIDs administered topically rather than orally.
      However, this constraint on the applicability of this PDDI is not stated implicitly: the formulation of the NSAID
      being described is ambiguous, and the importance of the means of administration is implied, but not stated directly.
      Describing PDDI evidence in terms of drugs in established drug terminologies, such as RxNorm
      (<a href="https://www.nlm.nih.gov/research/umls/rxnorm/">https://www.nlm.nih.gov/research/umls/rxnorm/</a>), will reduce ambiguity and enable computation through rules
      and inference used to turn the PDDI descriptions into actionable content for clinical decision support.
    </p>
    <p>
      The elements of the minimum information model demonstrate that, despite the readability of the example
      PDDI narrative, the information provided lacks both the structure and semantics necessary for effective
      decision support. Problems like these are not unique to the French Interactions médicamenteuses.
      For example, a search for the same Oral Anticoagulant / NSAID interaction executed at the drug
      ingredient level in the freely accessible database  DrugBank returns a single statement that vaguely
      describes the clinical effect but with no other information from the core items mentioned above:
    </p>
    <p style="text-align: center">“Ibuprofen may increase the anticoagulant activities of Warfarin.”</p>
    <p>
      As <a href="#COUMADIN-warfarin-product-label"></a> shows,
      slightly more information is provided in United States drug
      product labeling than in DrugBank but there are still many
      information gaps relative to the core PDDI information items
      suggested by conference series attendees (Bristol-Myers Squibb
      2017).
    </p>
    <figure id="COUMADIN-warfarin-product-label">
      <img src="W3C-Images/warfarin-product-label.png">
      <figcaption>An oral Anticoagulant / NSAID PDDI shown at the drug ingredient level
        from the United States drug product label for COUMADIN- warfarin sodium tablet (Bristol-Myers Squibb 2017). </figcaption>
    </figure>
    <p>
      Although missing information is the primary concern for the examples discussed, the minimum information
      model would also increase the utility of narratives that are abundant with information. For example, a
      search for oral anticoagulant / NSAID in the online interaction checking tool provided by Drugs.com returns
      a very detailed narrative that includes mention of clinical effect, mechanism, management options, some
      contextualized risk information, and specific citations of evidence (Drugs.com search 3/31/17). In this
      case, the minimum information model would be useful for suggesting how to provide structure and semantics
      to the description to best enable clinical decision support systems through the use of coded drugs names,
      clinical consequences, and contextual information and modifying factors.  The provision of these details
      in a standardized, computable form will facilitate integration of PDDI information with data in a patient's
      electronic health record, thus enabling patient-specific alerting and decision support.
    </p>
  </section>

  <section id="spec-user-stories">
    <h2>End-users of the minimum information model</h2>
    <p>
      Twelve user stories with related goals demonstrate the use of the
      PDDI minimal information model. These stories are associated
      with seven types of users (physicians, pharamacists, nurses,
      drug compendia editors, health science librarians, systems
      analysts, and content specialists: 
      <ul>
	<li><a href="#treatment-planning-phys">A physician conducting treatment planning</a> (3 distinct user stories)</li>
	<li><a href="#eval-management-options-phys">A physician evaluating management options</a></li>
	<li><a href="#eval-management-options-pharm">A pharmacist evaluating management options</a></li>
	<li><a href="#nurse-screening">A nurse screening for PDDIs</a></li>
	<li><a href="#editor-synthesis-dissemination">A drug compendium editor synthesizing PDDI evidence for dissemination</a></li>
	<li><a href="#librarian-dissemination">A health science librarian assisting in the synthesis of PDDI evidence for dissemination</a></li>
	<li><a href="#cds-team">A systems analyst and content
	specialist translating a synthesizes of PDDI evidence into a
	    clinical decision support tool</a></li>
	<li><a href="#med-rec-use cases">Pharmacists reonciling
	patient medications</a>
      </ul>
      
      Additional user types considered “out of scope” are listed in Appendix <a href="#out-of-scope-stories"></a>.
    </p>


    <p>Each user story was color coded
      for mention of core information items in the minimum information
      model (see <A HREF="#user-story-color-coding"></a>). Three user stories focused on the critical process 
      of medication reconciliation for PDDIS detailed in the Appendix
      (see <a href="#decision-trees"></a>) are given here; remaining user
      stories are located 
      in <a href="#final-stories"></a>. 
  </section>

  <section id="user-story-color-coding">
    <h2>Color codes used in user stories</h2>
    <p>The following table illustrates the colors used to describe
      user stories. Note that some of the elements (severity and frequency
      of exposure) are not addressed in any of the user stories.</p>

          <table>
        <tr>
          <td style="background-color: #fee087" width="150"></td>
          <td width="300" style="text-align: center">Clinical Consequences</td>
        </tr>
        <tr>
          <td style="background-color: #bed1f6" width="150"></td>
          <td width="300" style="text-align: center">Evidence</td>
        </tr>
        <tr>
          <td style="background-color: #dfa99f" width="150"></td>
          <td width="300" style="text-align: center">Recommended Actions</td>
        </tr>
        <tr>
          <td style="background-color: #a9d098" width="150"></td>
          <td width="300" style="text-align: center">Mechanism of Interaction</td>
        </tr>
        <tr>
          <td style="background-color: #d0c7e3" width="150"></td>
          <td width="300" style="text-align: center">Contextual Evidence/Modifying Factors</td>
        </tr>
        <tr>
          <td style="background-color: #f6bf8b" width="150"></td>
          <td width="300" style="text-align: center">Seriousness Rating</td>
        </tr>

        <tr>
          <td style="background-color: #ccffff" width="150"></td>
          <td width="300" style="text-align: center">Severity Rating</td>
        </tr>

	
        <tr>
          <td style="background-color: #a8a8a8" width="150"></td>
          <td width="300" style="text-align: center">Frequency of Harm</td>
        </tr>

        <tr>
          <td style="background-color: #ffcccc" width="150"></td>
          <td width="300" style="text-align: center">Frequency of Exposure</td>
        </tr>


  </table>
    
  </section>
  
  <section id="med-rec-use-cases">
    <h2>A set of user stories focused on medication reconciliation</h2>

      <section>
	<h2>Use Story 1:  Hospital Pharmacist, Medication Reconciliation upon Admission</h2>
	<ul>
          <li>A PDDI with unknown modifying factors:  Linezolid + SSRIs (sertraline)</li>
	</ul>
	<p>Beth is a hospital pharmacist who is reviewing the medications in the
          physician admission order for Bill, an
          <span style="background-color: #d0c7e3">85-year-old male
            dementia patient</span> who was transferred from a skilled nursing
          facility to the hospital after being diagnosed with a
          vancomycin-resistant Enterococcus faecium (VRE) infection.
          At the nursing home, Bill was prescribed sertraline to treat
          depression.  Beth receives an alert that linezolid, which is being
          considered to treat the VRE infection, has a potential interaction
          with the sertraline that Bill is currently taking.  <span style="background-color: #a9d098">Linezolid is a
            weak monoamine oxidase inhibitor</span>, and has been shown to
          <span style="background-color: #fee087">increase the
            risk of serotonin syndrome when taken concurrently with an SSRI such
            as sertraline</span>.  Beth would like to know the risks and benefits of
          continuing the sertraline and adding on the linezolid, the
          <span style="background-color: #f6bf8b">potential
            seriousness</span> of the interaction’s clinical consequence, and
          <span style="background-color: #dfa99f">recommended
            management options, such as selecting an alternative medication or
            discontinuing the sertraline</span>.  She would like to see the
          <span style="background-color: #bed1f6">current evidence
            behind the interaction</span>, so that she can determine if Bill has an
          increased risk of serotonin syndrome.  In order to gather this
          information, she reviews Bill’s history, lab results, and allergies
          from the health records faxed by his skilled nursing facility, as
          well as his medication list upon admission.  She reviews Lexicomp&trade;
          and the hospital’s intranet resources for additional information,
          but is having trouble finding information that is relevant to Bill’s
          situation.  She does a literature search using PubMed  in order to
          try to locate information about the
          <span style="background-color: #a8a8a8">frequency of adverse events in
            due to this potential interaction in other patients like Bill</span>, but
          she does not have access to all of the articles in the search results.</p>
      </section>
      <section>
	<h2>User Story 2:  Hospital Pharmacist, Medication
	Reconciliation upon Discharge</h2>

	<ul>
          <li>A PDDI that can (and should) be contextualized for specific patients or clinical circumstances:  KCL (potassium chloride) + K-sparing Diuretics (spironolactone)</li>
	</ul>
	<p>
          Beth is reviewing the physician’s discharge order for Maria.
          Maria is a <span style="background-color: #d0c7e3">72-year old woman</span>
          who was admitted to the hospital with
          <span style="background-color: #d0c7e3">acute decompensated heart failure</span>.
          While reviewing Maria’s medications,
          Beth sees that Maria is being discharged with spironolactone, a
          potassium-sparing diuretic that could potentially interact with the
          potassium chloride that Maria had been taking to treat low potassium
          levels.  Spironolactone <span style="background-color: #a9d098">may increase potassium levels in Maria’s blood,
            leading to hyperkalemia</span>.  Beth reviews Maria’s electronic health record
          in order to view her lab results and her other medications.  She sees
          that Maria is also
          <span style="background-color: #d0c7e3">taking the ACE inhibitor lisinopril for heart failure</span>,
          and since ACE inhibitors can also increase potassium levels, Beth would
          like to know how much this <span style="background-color: #d0c7e3">modifying factor</span>
          might increase Maria’s <span style="background-color: #fee087">risk of
            hyperkalemia</span> due to the interaction between potassium chloride and
          spironolactone.  Beth would like to know how likely it is that Maria
          will experience hyperkalemia, <span style="background-color: #f6bf8b">how serious hyperkalemia may be</span>, and
          <span style="background-color: #dfa99f">how to manage the interaction, such as by discontinuing one of Maria’s
            medications</span>.   Beth reviews the hospital’s intranet, as well as
          Micromedex&trade;, for recommendations.  She would also like more
          information about the potassium chloride that Maria was taking
          as one of her home medications, so she will need to contact
          Maria’s community pharmacy in order to find out the strength
          of the medication and if the prescription was still current.
	</p>
      </section>
      <section>
	<h2>User Story 3:  Consultant Pharmacist, Medication Reconciliation upon Readmission</h2>
	<ul>
          <li>A PDDI with a known, pharmacokinetic mechanism:  Warfarin + 2C9 inhibitors (metronidazole)</li>
	</ul>
	<p>
          Patrick is a nursing home consultant pharmacist who is reviewing the
          medications of a readmitted patient, Nancy.  Nancy is a
          <span style="background-color: #d0c7e3">78 year-old
            woman</span> who is being transferred back to her skilled nursing facility
          after a hospital admission for a Clostridium difficile (C. diff)
          infection; prior to the hospital admission, she was prescribed
          warfarin at the skilled nursing facility for <span style="background-color: #d0c7e3">deep vein thrombosis
            (DVT) treatment</span>.  Based on the hospital discharge summary, it
          appears that Nancy was taken off of the warfarin at the hospital
          due to an increased INR, and returned to the skilled nursing
          facility without an order for warfarin.  Patrick sees that a
          potential interaction may occur with the warfarin that Nancy
          had been prescribed prior to her hospitalization, and the
          metronidazole now used to treat her infection, since
          <span style="background-color: #a9d098">metronidazole is a CYP2C9 inhibitor and may increase the
            plasma concentration of warfarin</span>.  A clinical consequence of
          this interaction would be an
          <span style="background-color: #fee087">increased INR leading to an increased
            risk of bleeding</span>.  Patrick would like to gather
          <span style="background-color: #dfa99f">management
            recommendations</span> for this interaction prior to contacting Nancy’s
          physician.  He is interested in Nancy’s duration of therapy for
          both the warfarin and the metronidazole, her current risk factors
          for a DVT, and if she is indicated for prophylactic therapy.
          Patrick also wants to know <span style="background-color: #dfa99f">if and when warfarin should be restarted,
            and at what dose, in order to reduce the risk of bleeding due to
            the interaction</span>.  He would also like to know <span style="background-color: #dfa99f">if metronidazole is
            the best option to continue treating Nancy’s C. diff infection,
            or if there is an alternative option that may not interact with
            warfarin</span>.  To gather this information, he reviews Nancy’s
          previous INR values, medication list, and history.  He also
            contacts the hospital to determine whether warfarin
          had been given at any point during Nancy’s stay, if the dosage
          had been adjusted, what other medications she was given, and if
          any of her other medications were discontinued.  He reviews
          his company’s intranet resources for additional information about
          the interaction and possible <span style="background-color: #dfa99f">evidence-based recommendations</span>.
          Finally, Patrick is interested in the <span style="background-color: #a8a8a8">frequency of serious bleeding
            events </span><span style="background-color: #d0c7e3">in geriatric patients co-prescribed warfarin and
            metronidazole</span>, and the <span style="background-color: #bed1f6">literature surrounding the interaction</span>.
	</p>
      </section>
    </section>
  </section>

<section id="KR-discussion">
  <h2>Knowledge representation for the minimal information model</h2>

The wide range of potential use cases for the information model
requires flexibility in the knowledge representation. Moreover, the
  number of pre-existing ontologies relevant to this domain clearly
  demonstrates the richness of the domain [[herrero-zazo-2015]]. To
  keep the minimum information model lean and ensure its
  maintainability and usability, it was necessary to develop a clear
  scope for the knowledge representation including 
issues such as:

<ul>
  <li> How should terms related to the core information items
  (see <a href="#user-centered-def"></a>) be modeled?</li>

  <li>What is the role of an upper ontology?</li>
  
  <li>What is the relationship between  the core information items and other existing ontologies?</li>

  <li>Should terms from other resources, such as medical terminologies, be reused?</li>

</ul>

The following strategies are suggested for the representation of PDDI
minimal information (see <a href="#kr-process-apdx"></a> for a
description of the process used to develop these recommendations):

<ol>
  <li>The Minimum PDDI Information Ontology
      (<a href="https://github.com/MPIO-Developers/MPIO"
      target="new">MPIO</a>) should be used for the core information
      items relevant to the PDDI domain (see 
      Section <a href="#user-centered-def"></a>). The ontology is
      limited in its semantic richness by design, but remains
      compatible with semantically rich models such as <a target="new"
      href="http://purl.obolibrary.org/obo/dideo.owL"> the Drug-drug
      Interaction and Drug-drug Interaction Evidence Ontology
      (DIDEO)</a> and <a target="new"
      href="http://purl.obolibrary.org/obo/dinto.owl">the Drug-Drugs
      Interaction Ontology (DINTO)</a>.
  </li>
  <li> The MPIO is written in
      the <a href="http://www.w3.org/TR/owl2-primer/">Web Ontology
      Language (OWL 2)</a> [[owl2-overview]]. The individual classes
      in the MPIO are sub-classes of classes provided by
      the <a href="https://github.com/bfo-ontology/BFO/wiki"> Basic
      Formal Ontology (BFO)</a> upper ontology. This enables
      integration with numerous other ontologies written in OWL 2 that
      use the same upper ontology. This approach fosters integration
      with a number of existing formal ontology efforts including
      DIDEO, DINTO, <a href="http://obi-ontology.org/"
      target="new">Ontology for Biomedical Investigations</a>, and
      the <a href="http://www.oae-ontology.org/"> Ontology of Adverse
      Events</a>.


  </li>
  <li>The core PDDI information items in the MPIO are
       all <a href="http://purl.obolibrary.org/obo/IAO_0000030">information
       content entities</a>. This approach is chosen to reflect the
       hypothetical nature of the information represented. As
       abstract descriptions of events and relationships that might occur,
       instances of the PDDI model do not make any claims that these
       interactions must actually exist.  However, as OWL models are
       generally interpreted to discuss objects that exist in the
       world, knowledge representations must take care to avoid
       making these claims of any of the PDDI information. To addres
       this problem, MPIO classifies items in the minimal information
       model as <em>information content entities</em>, essentially
       saying that they are &quot;about some thing&quot; Thus, each
       element of the model essentially exists as a statement about
       the PDDI.  As a result, the OWL 2 entities do not
      refer to the actual material entities or processes. Rather, all
      properties of the core information items are terminological in
      nature and refer to relations between the term and other
      terms. For example, the core term <a>Mechanism of
      Interaction</a> does not represent an entity that has
      participants or is preceded by another biological process. Those
      would be properties of material processes that would be invoved
       if the interaction were actually realized. Instead, the MPIO
      term <a>Mechanism of Interaction</a> is an information
      content entity provides information about those material
      processes. It is up to other ontologies, such as DIDEO or DINTO,
      to provide a detailed representation of the underlying
      biomedical processes, qualities, and material entities.  These
      representations will be complementary to the core information
      items in MPIO.
  </li>
  <li>An important requirement of the PDDI minimum information model
      is that it allow for integration of terms from existing
      biomedical terminologies such as ICD-10, SNOMED-CT, RxNorm, and
      LOINC. This presents a challenge since these terminologies
      represent similar items at different levels of semantic richness,
      methodological rigor, and semantic commitments. While it is
      highly unlikely that it would be possible to unify all external
      terms semantically at an upper level with the core PDDI
      information items (see
      Section <a href="#user-centered-def"></a>), terms for which a
      human understandable, non-circular, definition exist, MAY be 
      re-used in the MPIO. Re-use SHALL be accomplished by
      representing an information content entity about the object
      referenced by the term. For example, the diagnosis referred to
      by a diagnostic code from ICD 10 would be reused in the MPIO by
      representing an information content entity corresponding to the
      ICD 10 code. Practically speaking, concepts from any of the
      terminologies might be used, but they should represented
      whenever possible by unambiguous identifiers for both the source
      terminology and the specific concept.
  </li>
</ol>  
  
</section>

<section>
  <h2>Discussion</h2>
  <p>
    The information provided in this Community Group Note provides a
    concrete, user centered, basis for design and implementation
    activities for the PDDI minimum information model. Twelve user
    stories with related goals show how the PDDI minimum information
    model would support various users
    (see <a href="#spec-user-stories"></a>).  Detailed descriptions of
    more than a dozen PDDIs, including specific clinical contexts,
    were constructed (see <a href="#decision-trees"></a>). Non-ambiguous definitions
    were created for PDDI core information items and implemented in a
    new an open source ontology (see
    Sections <a href="#user-centered-def"></a>
    and <a href="#KR-discussion"></a>). Two example PDDIs were
    annotated with the core information items along with detailed
    recommendations (see
    Sections <a href="#ex-warfarin-nsaids"></a>
    and <a href="#ex-tki-ppi"></a>. A subset of the user stories and
    selected PDDIs were integrated into three medication
    reconciliation use cases (see Section
    <a href="#med-rec-use-cases"></a>).
  </p>
  <p>
    The next sub-sections provide a discussion of three potential
    applications of the minimum information that are shown
    in <a href="#PDDI-MI-APPLICATIONS"></a>. 
  </p>

  <section>
    <h2>Shareable PDDI Clinical Decision Support Using HL7 Standards </h2>
    <p>
      The creation and maintenance of PDDI clinical decision support
      (CDS) generally requires considerable time and energy from
      highly trained domain experts. An additional need is to
      standardize the electronic health records context that is used
      to trigger CDS services. This can include context parameters
      that currently might not available but that, if present, would
      be useful for increasing the specificity of the PDDI CDS
      alerts. Achieving this sort of standardization is important to
      ensure that PDDI decision support can be implemented across a
      variety of systems.
    </p>
    <p>
      Fast Health Interoperability Resources (FHIR) provides a
      possible solution to the challenge of seamless information
      exchange and data interoperability of information resources in
      health care related environments
      [[bender-2013]][[mandel-2016]]. FHIR  provides a collection of 
      specifications for resources 
      in healthcare settings for the purpose of overcoming the data
      exchange challenges in healthcare.  FHIR defines a set of
      standardized data models for health care covering key areas
      including Clinical information, Diagnostics, and
      Medications. For instance, the Medication resource contains
      medication codes, ingredient details, packaging information and
      related information. FHIR resources are API-based, making it
      possible for third party systems to access electronic health
      records data for the purpose of supporting new use cases.
    </p>
    <p>
      FHIR encodings of PDDI information could form the basis of
      information exchange for more standardized PDDI clinical
      decision support. Indeed, a
      new <a href="http://wiki.hl7.org/index.php?title=PDDI_CDS"
      target="new"> HL7 project related to PDDI decision support</a>
      has been recently approved by the
      HL7 <a href="http://wiki.hl7.org/index.php?title=Clinical_Decision_Support_Workgroup"
      target="new">Clinical Decision Support</a>
      and <a href="http://wiki.hl7.org/index.php?title=Pharmacy_WG"
      target="new">Pharmacy Workgroups</a>. The project seeks to
      develop an implementation guide for PDDI CDS that will specify
      both a knowledge representation format for PDDI logic and CDS
      services for PDDI with electronic health record (EHR)
      systems. Specifically, the implementation guide will include
      specifications for:

      <ol>
	<li>How to represent PDDI logic in the
	  HL7 <a href="http://wiki.hl7.org/index.php?title=Clinical_Quality_Language"
	  target="new">Clinical Quality Language</a> (CQL) using the FHIR Clinical Reasoning
	  module.</li>
	<li>How to use the emerging <a href="https://cds-hooks.org/"
	   target="new">CDS Hooks</a> standard as a mechanism for
	   electronic health records to request PDDI CDS from CDS
	   services.</li>
      </ol>
    </p>
    <p>
      As is stated in
      the <a href="https://github.com/HL7/PDDI-CDS/blob/master/Documents/ProjectScopeStatement/PDDI%20CDS%20PSS%2002-15-2018.docx?raw=true"
      target="new">project's scope statement</a>, the HL7 PDDI CDS
      project will draw from the technical foundation, PDDI
      information, and user centered design artifacts reported in this
      Community Group Note. It is anticipated that representation of
      PDDI minimal information may  require the creation of new FHIR
      resource(s) (e.g., a resource       to represent drug
      interactions) and/or FHIR profile(s) (e,g, for 
      PDDI context representation). At the time of this writing,
      participation in the PDDI CDS project is open to public
      participation. Person interested in participation can find more
      information on the <a target="new"
      href="http://wiki.hl7.org/index.php?title=PDDI_CDS">HL7 PDDI CDS
      project wiki</a>.
    </p>
  </section>

  <section>
    <h2>Enhancing the Drug-drug Interaction Section of Structured Product Labeling</h2>
    <p>
      Serious consequences for patients could result if information
      about known drug interactions is missing from a drug’s product
      labeling. To address this potential risk, the United States Food
      and Drug Administration (FDA) mandated in 2006 that all product
      labels for FDA-approved prescription drugs include clinically
      significant interactions (c.f., CFR 21 201.57(c)(8)), as well as
      the results of pharmacokinetic studies that establish the
      absence of effect (c.f., CFR 21 201.57(c)(13)(C)) (Code of
      Federal Regulations Title 21). Similar requirements have been
      enacted by the European Medicine's Agency for their equivalent
      of product labeling
      called <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248251/"
      target="new">Summary of Product Characteristics</a>.
    </p>
    <p>
      As mentioned in a previous section
      (see <a href="#overarching-use-case"></a>), drug product
      labeling can contain many gaps in information relative to the
      core PDDI information. Other prior work has shown that many
      known PDDIs are not mentioned in drug labels [[boyce-2013]]. This problem is not unique to United States
      labeling. For instance, Pfistermeister et al. reported that
      critical drug–drug interaction warnings are frequently missing,
      or are mentioned inconsistently in the United States, United
      Kingdom, and German labels of the involved drugs [[pfistermeister-2014]].
    </p>
    <p>
      As is shown <a href="#PDDI-MI-APPLICATIONS"></a>, the PDDI
      minimum information model could help address this issue by making PDDI information reported in product labeling more
      complete and clinically useful. In the United States and other
      parts of the world, the content of a drug's product label is
      written by the company that owns the drug as part of the drug
      approval process. There is currently no information model to
      guide product label authors as they write drug interaction
      information. The PDDI minimum information model could provide
      authors with clear guidance on the core information items that
      they should discuss. 
    </p>
    <p>
      This approach might require an annotation tool to help authors
      tag the core PDDI information items correctly and
      consistently. Once the PDDI information is authored using the
      minimum information model, it could be published in a
      computer readable format. In the United States, this would 
      currently be accomplished using
      the <a href="https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/"
      target="new"> Structured Product Label (SPL)</a> standard. Other
      standards, such as
      the <a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001849.jsp&mid=WC0b01ac0580bf85bb"
      target="new"> International Organization for Standardization
      (ISO) for the identification of medicinal products (IDMP)</a>
      serve a similar function outside of the United States. Focusing
      on the United States as case study, SPLs are XML documents
      written using the HL7 SPL specification that the FDA requires
      industry to use when submitting drug product label content (FDA
      2005). The
      HL7 <a href="https://www.hl7.org/Special/committees/rcrim/overview.cfm"
      target="new">Biomedical Research and Regulation</a> developed
      and maintains the SPL standard. Currently, the SPLs for all drug
      products marketed in the United States are available for
      download from the National Library of Medicine's DailyMed
      resource (National Library of Medicine 2017). At the time of
      this writing, DailyMed provides access to drug product labeling
      for more than 30,000 prescription products.
    </p>
    <p>
      PDDI information annotated using the minimum information model
      could be published in a computer readable format using what is
      called an SPL <i>supplemental       indexing
      file</i>. Supplemental indexing files provide additional useful
      information augmenting official FDA drug  SPLs. Currently,
      supplemental indexing is used to specify pharmacologic classes,
      billing units, warning letter alerts, and other information
      (National Library of Medicine 2017). Supplemental indexing files
      including the elements of the  PDDI minimum information model
      might be stored in XML and, trough the use of XSL and XSLT,
      be used to render the data in various formats including HTML,
      and PDF, and character-delimited tables. 
    </p>
  </section>

  <section>
    <h2>Highlighting and Filling Gaps in Evidence Needed to Develop PDDI Decision Support</h2>
    <p>
      Existing PDDI knowledge is heterogeneous with respect to
      coverage of the core information elements. For example,
      frequency of exposure and frequency of harm evidence was not
      available for either of the two PDDI examples detailed in this
      Note (see Sections <a href="#ex-warfarin-nsaids"></a>
      and <a href="#ex-tki-ppi"></a>). Other examples of knowledge
      gaps are mentioned in Appendix <a href="#decision-trees"></a>,
      such as the poorly understood mechanism of the PDDI between
      warfarin and Ifosfamide/Etoposide.
    </p>
    <p>
      Part of the reason that there are many knowledge gaps is that
      many drug interactions are identified in case reports or
      observational studies that provide little or no indication of
      causal mechanisms. Other interactions, especially
      pharmacokinetic interactions, are established based on small
      clinical studies that rarely suggest a clinical
      consequence. Still other interactions might be inferred from the
      pharmacodynamic properties of two drugs, leaving unanswered
      questions about contextual factors that might increase or
      mitigate patient risks. Moreover, gaps in knowledge can exist
      about the risk factors or appropriate management options for a
      given interaction, even when solid evidence is available for its
      existence, the mechanism of its occurrence, and the likely
      clinical consequence from exposure.
    </p>
    <p>
      The information model can also act as a template for drug
      epxperts to use while synthesizing PDDI evidence. As the experts
      compile evidence for each of the core information
      categories, critical gaps in knowledge will become apparent.
      These gaps might be used to develop prioritized research agendas
      aimed at providing evidence for clinical recommendations. 
    </p>
    <p>
      Similarly, the PDDI model might be used to address knowledge
      gaps through the creation of computable cohort descriptions —
      serialized queries that  combine  concept sets with logical
      operations to extract specific patient sub-populations from a
      clinical data repository. Computable cohort descriptions are a
      cornerstone for research on PDDIs using real world data. A
      recent project showed the feasibility of converting PDDI
      descriptions created as part of this Note to  computable cohort
      definitions [[rosko-2017]]. The target for 
      translation was the Atlas clinical research tool created by the
      Observational Data Health and Informatics collaborative. Atlas
      has a powerful interface for creating, running, and sharing
      cohort descriptions [[ohdsi-atlas]]. Once created, the
      cohort descriptions were executed over a clinical dataset for a
      simulated population stored in the OHDSI common data model. The
      code, concept sets, and cohort descriptions for the
      demonstration are stored
      in <a href="https://github.com/dbmi-pitt/iDIA_Rules">a GitHub
      repository</a>
      and <a href="https://github.com/dbmi-pitt/docker-iDIA-Rules">Docker
	container</a>.
    </p>
  </section>
</section>


<section>
  <h2>Conclusion</h2>
  <p>
    This Community Group Note provides motivation and a detailed
    domain analysis for a minimum information model for PDDI
    information. The Note also suggests potential applications of the
    minimum information model that could lead to improvements in
    patient safety with respect to PDDIs. The overarching goal of
    these contributions is to provide a technical foundation for
    effective PDDI clinical decision support. A reference
    implementation of the information model is the subject of future
    work.
  </p>
</section>

<section>
  <h2>Acknowledgments</h2>
  <p>
  Development of this Community Group Note was partially supported by
  a grant from the United States National Library of Medicine
  (R01LM011838) and Agency for Healthcare Research and Quality
  (R21-HS023826). The opinions expressed in this note do not
  necessarily reflect the opinions of the funding agencies.
  </p>
</section>

<section class="appendix">
  <h2>Appendices</h2>
  <section id="development-process">
    <h2>Development Process</h2>

    <p>Toward the goal of developing such a model, a volunteer-based Task Force force was formed by the Health
      Care and Life Sciences Interest Group, an interest group that operates publicly through the World Wide
      Web Consortium (W3C).  This Task Force has taken a user-centered design approach to designing the
      minimal information model through the a series of complementary activities:</p>
    <ol>
      <li>Development of decision trees of more than a dozen PDDIs to
	represent  using the new information model.</li>
      <li>Creation of user stories and use cases that define the
        requirements for the minimum information model.</li>
      <li>Definition of guidelines for knowledge representation</li>
    </ol>

    <section id="Decision-Trees">
      <h2>Decision Trees</h2>
    <section id="selecting-PDDIs">
      <h2>Selecting PDDIs to implement using the minimum information
	model</h2>

      <p>Prior work by some members of the Task Force has sought to develop evidence-based clinical
        algorithms that consider a patient’s electronic health record information to provide a clinician
        with actionable information tailored to the patient’s specific context. <sup>1</sup>The algorithms are formulated
        as decision trees to provide concise information including the interaction description, the purported
        mechanism and possible effects, the evidence supporting the mechanism and effects along with citations
        listed in the footnotes. Two sample decision trees illustrating the management options can be found in
        the appendix (see Appendix <a href="#decision-trees">DECISION TREES</a>).</p>
      <blockquote style="font-size: small"><sup>1</sup>The initial decision trees were developed through the “Individualized Drug Interaction Alerts”
        AHRQ grant by Task Force members Dan Malone and John Horn, as well as Phil Hansten (AHRQ Project: R21-HS023826-01;
        Title: Individualized Drug Interaction Alerts; Authors: Daniel C. Malone, University of Arizona; John Horn,
        Philip Hansten, University of Washington).</blockquote>
      <p>The Task Force built on this prior work by selecting PDDIs to demonstrate the new minimum
        information model and then creating decision trees for each of the PDDIs that they selected.
        Task Force drug experts selected the PDDIs and identified contextual information/modifying factors that
        would warrant any of three different recommended actions - <em>No special precautions, Assess risk and take action
          if necessary, and Use only if benefit outweighs risk</em>. Draft decision trees were presented during sub-team
        monthly meetings for thorough discussion. Revisions were made iteratively until the group reached consensus
        on the presented drafts and finalized the decision trees.</p>
      <p>
        The Task Force began with a discussion of how to select the PDDIs for developing decision trees.
        One option was to select the most serious PDDIs. However, it was noted that the seriousness of a PDDI
        depends a great deal on the patient characteristics context. This meant that it would be difficult to
        identify PDDIs that were considered the most serious in all clinical settings and for all patients. An
        alternative approach was to choose PDDIs that would allow the Task Force to demonstrate how the
        information model should be used when facing known issues with PDDI evidence and knowledge. Toward that
        aim, participants were requested to provide suggestions of PDDIs meeting at least one or more of the
        following criteria which follow from the aforementioned information categories suggested by attendees
        of the multi-stakeholder conference meetings/series mentioned in Section <a href="#justification"></a>:
      </p>
      <ol type="A">
        <li>The interaction could (and should) be contextualized for specific patients or clinical circumstances.</li>
        <li>The interaction applies at the drug class level.</li>
        <li>The interaction does not apply at the drug class level.</li>
        <li>The mechanism is known and is pharmacokinetic.</li>
        <li>The mechanism is known and is pharmacodynamic. </li>
        <li>The mechanism is poorly described, not well elucidated.</li>
        <li>The evidence supporting the interaction is strong.</li>
        <li>The evidence supporting the interaction is weak.</li>
        <li>The frequency of exposure data is available.</li>
        <li>The frequency of exposure data is not available.</li>
        <li>The frequency of adverse event data is available.</li>
        <li>The frequency of adverse event data is not available.</li>
        <li>The recommended action is “monitor” or “take note”.</li>
        <li>The recommended action is “avoid”.</li>
        <li>The recommended action is “a clear alternative drug and dose”.</li>
      </ol>

    </section>
    <section id="decision-trees">
    <h2>Decision Trees Created for the Minimum Information Model Domain Analysis</h2>
    The Task Force force developed 14 PDDI decision trees detailing
      the steps taken in using the the minimal information model to
      describe PDDIS.  These exemplars were chosen to represent
      questions identified by the Task Force force as potentially
      affecting the search and syntheses of PDDI information. The
      potential interactions and the information situations they were
    selected for are listed in <em>Table 1</em>. Value sets defining
    relevant drug classes and clinical consequences are given in <A HREF="#Value-Sets"></a>. </p>

    <p><strong><em>Table 1</em></strong></p>
    <table>
      <tr>
        <th width="200">Exemplar potential drug-drug interactions</th>
        <th width="150">Drug or Drug Class 1</th>
        <th width="150">Drug or Drug Class 2</th>
        <th width="300">Explanation/Justification</th>
      </tr>
      <tr>
        <td rowspan="2">Can (and should) be contextualized for specific patients or clinical circumstances</td>
        <td>Tamoxifen</td>
        <td>Paroxetine</td>
        <td>Patients with extensive CYP2D6 status on paroxetine will derive no benefit from tamoxifen. (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).
	</td>
      </tr>
      <tr>
        <td>Potassium (KCL)</td>
        <td>Potassium-sparing Diuretics</td>
        <td>Combination has known patient-specific risk factors. <strong><font color="red">(Status: Completed as part of the iDIA project -- need permission before releasing to this project's github)</font></strong></td>
      </tr>
      <tr>
        <td>Applies at the class level</td>
        <td>Monoamine Oxidase Inhibitors (MAOIs)</td>
        <td>Indirect Sympathomimetics</td>
        <td>A class interaction involving all drugs in the class. (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).</td>
      </tr>
      <tr>
        <td>Does not apply at the class level</td>
        <td>Tyrosine Kinase Inhibitors</td>
        <td>Proton Pump Inhibitors</td>
        <td>Not all Kinase inhibitors have pH dependent absorption. Imatinib, nilotinib, dasatinib, bosutinib, and ponatinib are BCR‐ABL tyrosine kinase inhibitors. Imatinib and ponatinib do not have a significant interaction due to pH dependent absorption with proton pump inhibitors, whereas nilotinib, dasatinib, and bosutinib do (Lexi‐comp and Micromedex). (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).</td>
      </tr>
      <tr>
        <td rowspan="2">The mechanism is known and is pharmacokinetic</td>
        <td>Warfarin</td>
        <td>CYP2C9 Inhibitors (ie. Bactrim)</td>
        <td>A CYP-mediated pharmacokinetic interaction. <strong><font color="red">(Status: In Process)</font></strong></td>
      </tr>
      <tr>
        <td>Digoxin</td>
        <td>Cyclosporin</td>
        <td>A transport protein (p-glycoprotein) mediated interaction. <strong><font color="red">(Status: In Process)</font></strong></td>
      </tr>
      <tr>
        <td>The mechanism is known and is pharmacodynamic</td>
        <td>Epinephrine</td>
        <td>Beta-Blockers</td>
        <td>The interaction is different differentiates between selective and non-selective beta blockers. The clinical outcome is a; hypertensive crisis. <strong><font color="red">(Status: Completed as part of the iDIA project -- need permission before releasing to this project's github)</font></strong></td>
      </tr>
      <tr>
        <td>The mechanism is not well elucidated/known</td>
        <td>Warfarin</td>
        <td>Ifosfamide/Etoposide</td>
        <td>Drugs for treating cancers of the blood drugs. - Clinical effect is INR change buts no mention of what mechanism could be found. (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).</td>
      </tr>
      <tr>
        <td rowspan="2">The evidence supporting the interaction is strong</td>
        <td>Epinephrine</td>
        <td>Beta-Blockers</td>
        <td>Widely known interaction with considerable available evidence. <strong><font color="red">(Status: Completed as part of the iDIA project -- need permission before releasing to this project's github)</font></strong></td>
      </tr>
      <tr>
        <td>Simvastatin, Atorvastatin, Lovastatin</td>
        <td>Clarithromycin</td>
        <td>Widely known interaction with considerable available evidence. <strong><font color="red">(Status: In Process)</font></strong></td>
      </tr>
      <tr>
        <td>The evidence supporting the interaction is weak</td>
        <td>Warfarin</td>
        <td>Antibiotics that don't inhibit CYP2C9</td>
        <td>Hard to find evidence for the interaction. <strong><font color="red">(Status: In Process)</font></strong></td>
      </tr>
      <tr>
        <td>The frequency of exposure data is available</td>
        <td>Warfarin</td>
        <td>Non-steroidal anti-inflammatory drugs (NSAIDs)</td>
        <td>Paper by Malone et al. - National sample. (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).</td>
      </tr>
      <tr>
        <td>The frequency of exposure data is not available</td>
        <td>Simvastatin</td>
        <td>Fluconazole</td>
        <td>Based on literature search. (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).</td>
      </tr>
      <tr>
        <td>The frequency of adverse event data is available</td>
        <td>Spironolactone</td>
        <td>Potassium supplements</td>
        <td>Associated with Risk of hospitalization. <strong><font color="red">(Status: Completed as part of the iDIA project (KCL and K-sparing diuretics) -- need permission before releasing to this project's github)</font></strong></td>
      </tr>
      <tr>
        <td>The frequency of adverse event data is not available</td>
        <td>Simvastatin</td>
        <td>Fluconazole</td>
        <td>Literature search did not find frequency of adverse event data. (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).</td>
      </tr>
      <tr>
        <td>The recommended action is “monitor” or “take note”</td>
        <td>Potassium (KCL)</td>
        <td>Potassium-sparing Diuretics</td>
        <td>See explanation above. <strong><font color="red">(Status: Completed as part of the iDIA project -- need permission before releasing to this project's github)</font></strong></td>
      </tr>
      <tr>
        <td>The recommended action is “avoid”</td>
        <td>Monoamine Oxidase Inhibitors (MAOIs)</td>
        <td>Indirect Sympathomimetics</td>
        <td>See explanation above. (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).</td>
      </tr>
      <tr>
        <td>The recommended action is a clear alternative drug and dose</td>
        <td>Simvastatin</td>
        <td>Amiodarone</td>
        <td><a href="http://www.fda.gov/Drugs/DrugSafety/ucm283137.htm">http://www.fda.gov/Drugs/DrugSafety/ucm283137.htm</a> (Status: completed, see <a href="https://github.com/W3C-HCLS/w3c-ddi/tree/master/Decision-trees">the project on github</a>).</td>
      </tr>
    </table>
    <section id="warfarin-nsaids-dt">
      <h2>Example PDDI:Warfarin + NSAIDs (Draft)></h2>
      <p>
        Non-steroidal anti-inflammatory drugs (NSAIDs) have antiplatelet effects which
        increase the bleeding risk when combined with oral anticoagulants such as warfarin.
        The antiplatelet effect of NSAIDs lasts only as long as the NSAID is present in the
        circulation, unlike aspirin’s antiplatelet effect, which lasts for up to 2 weeks
        after aspirin is discontinued. NSAIDs also can cause peptic ulcers and most of the
        evidence for increased bleeding risk with NSAIDs plus warfarin is due to upper
        gastrointestinal bleeding (UGIB).
      </p>
      <figure id="Warfarin-NSAID-TREE">
        <img src="W3C-Images/Warfarin-NSAID-TREE.png">
        <figcaption> <span style="color: #30d529">¢</span> = No special precautions.
          <span style="color: #f9bd3b">n</span> = Assess risk and take action if necessary.
          <span style="color: #fb0082">u</span> = Use only if benefit
          outweighs risk. Originally
	    developed through &quot;Individualized Drug
	    Interactions&quot; (AHRQ Project R21-HS023826-01) by Task
	      Force Members Daniel Malone, John Horn, and Philp Hansten.</p>
	    

          <p style="text-align: left"><strong>Footnotes:</strong></p>
          <ol type="1">
            <li style="text-align: left">Topical diclofenac has relatively low systemic absorption; in one study a topical gel (16 g/day) produced about 6% of the absorption seen with systemic administration of 150 mg/day. A higher than recommended dose of topical gel (48 g/day) produced 20% of a systemic dose of diclofenac.</li>
            <li style="text-align: left">If the NSAID is being used as an analgesic or antipyretic, it would be prudent to use an alternative such as acetaminophen. In some people, acetaminophen can increase the anticoagulant effect of warfarin, so monitor the INR if acetaminophen is used in doses over 2 g/day for a few days. For more severe pain consider short-term opioids in place of the NSAID.</li>
            <li style="text-align: left">Proton pump inhibitors and misoprostol may reduce the risk of UGIB in patients receiving NSAIDs and warfarin.</li>
            <li style="text-align: left">Patients with a history of UGIB or peptic ulcer may have an increased risk of UGIB from this interaction. The extent to which older age is an independent risk factor for UGIB due to these interactions is not firmly established, but UGIB in general is known to increase with age.</li>
            <li style="text-align: left">Both corticosteroids and aldosterone antagonists have been shown to substantially increase the risk of UGIB in patients on NSAIDs, with relative risks of 12.8 and 11 respectively compared to a risk of 4.3 with NSAIDs alone [[masclee-2014]]</li>
          </ol>
        </figcaption>
      </figure>
    </section>
    <section id="BCR-ABL">
      <h2>Example PDDI: BCR-ABL Tyrosine Kinase Inhibitors (TKI) + Proton Pump Inhibitors (PPI)</h2>
      <p>
        BCR-ABL Tyrosine Kinase inhibitors bosutinib, dasatinib, imatinib, nilotinib, and
        ponatinib are indicated for Philadelphia chromosome-positive chronic myeloid leukemia.
        Ponatinib is only approved in T315I-positive patients. These TKIs demonstrate pH dependent
        absorption for oral administration which may result in decreased efficacy when given
        concomitantly with medications that increase gastric pH.  Dasatinib area under the curve
        (AUC) is decreased when co-administered with antacids, H2 antagonists, and PPIs.<sup>2</sup> Bosutinib and nilotinib AUCs are decreased with concomitant PPIs but antacids and H2
        antagonists may be considered if TKI is given 2 hours before the antacid/H2 antagonist.<sup>3,4</sup>
        However, for nilotinib a retrospective study has shown no difference in cytogenetic response
        rates for patients taking PPIs.<sup>5</sup>  Imatinib and ponatinib AUCs are not appreciably decreased
        by PPI co-administration.<sup>6,7</sup>
      </p>
      <figure>
        <img src="W3C-Images/BCR-ABL-tree.png">
        <figcaption><span style="color: #30d529">¢</span> = No special precautions.
          <span style="color: #f9bd3b">n</span> = Assess risk and take action if necessary.
          <span style="color: #fb0082">u</span> = Use only if benefit
          outweighs risk. Originally developed through &quot;Addressing gaps
	   in clinically useful evidence on drug-drug interactions&quot; (R01LM011838)
	   NIH Grant by Task Force Members Evan Draper, Daniel
	     C. Malone, John Horn, and Philip Hansten. <br>

	  <p style="text-align: left"><strong>Footnotes:</strong></p>
          <ol type="1">
            <li style="text-align: left">[[sprycel-2015]]</li>
            <li style="text-align: left">[[bosulif-2015]]</li>
            <li style="text-align: left">[[tasigna-2015]]</li>
            <li style="text-align: left">[[yin-2012]]</li>
            <li style="text-align: left">[[iclusig-2016]]</li>
            <li style="text-align: left">[[egorin-2009]]</li>
          </ol>
        </figcaption>
      </figure>
    </section>
    </section>
</section>


<section id="user-stories-goals">
  <h2>User Stories</h2>

        <section id="user-story-workflow">
      <h2>Workflow for arriving at stories and goals</h2>
      <p>
        User stories and goals were developed in order to showcase how the PDDI minimum information model
        will support users. The Task Force began developing the Stakeholder Description document and
        the PDDI Minimum Information Model User Scenarios document in order to identify key users. These
        stakeholder descriptions and user scenarios were used as the basis for further brainstorming with
        the assistance of a user experience expert to develop a master list of tasks, users, information needs,
        information values, and barriers to drug-drug interaction based decision-making in a variety of situations.
        A core set of user types was selected for development of user stories based on the scope of the minimum
        information model. 
      </p>
      <p>
        To develop the user stories for the core user types, Task Force  members created an
        initial information needs list  and then was supplemented it with user interviews, interview transcripts
        collected as a part of a recently published manuscript on PDDI information needs of drug information
        compendium editors [[romagnoli-2017]], and the published literature. Where possible, user stories
        were based on PDDIs suggested by the Task Force’s PDDI experts. All user stories were reviewed
        during team meetings to solicit feedback and comments. Based on Task Force member suggestions,
        the user stories were edited to make them more clinically relevant, accurate and appropriate. Information
        model items were highlighted based on a color-coded key to indicate the minimum information model
        information item in question.
      </p>

      
    </section>

  <section id="final-stories">
    <h2>User stories for the minimum information model</h2>
	The following user stories use the
	color-coding described
	in <A href="user-story-color-coding"></a> to represent core
	information items defined for the minimum information model. A
	table 
	summarizing the information needs exposed by these use cases is also presented in  Appendix <a href="#med-rec-needs"></a>.
      </p>

      <section id="treatment-planning-phys">
        <h2>Treatment Planning, Physician</h2>
        <p><strong>Simvastatin + Amiodarone</strong></p>
        <ul>
          <li>Kathleen is a physician who is treating a patient who has a ventricular arrhythmia. Kathleen
            would normally prescribe amiodarone for this particular patient, but he is being treated with
            simvastatin for dyslipidemia, and she knows that a <span style="background-color: #f6bf8b">potentially serious interaction</span> may occur
            leading to <span style="background-color: #fee087">rhabdomyolysis</span>.  Kathleen wants to know <span style="background-color: #d0c7e3">what the patient’s risk factors are for
              rhabdomyolysis</span>, what the benefits and risks would be to <span style="background-color: #dfa99f">switching him to an alternative statin</span>,
            and if amiodarone is not the best option for this patient, what <span style="background-color: #dfa99f">alternatives to amiodarone</span> exist
            for this patient, and what the available <span style="background-color: #bed1f6">evidence</span> shows in terms of ventricular arrhythmia
            patient outcomes.</li>
        </ul>
        <p><strong>(Pediatrics) Fluoxetine + Ondansetron</strong></p>
        <ul>
          <li>Evelyn is a pediatric emergency medicine physician caring for an adolescent with a history
            of major depressive disorder treated with fluoxetine, who presents with acute onset of
            vomiting and diarrhea.  Evelyn’s usual first-line antiemetic for acute gastroenteritis is
            ondansetron, but Evelyn knows that both fluoxetine and ondansetron are listed as
            <span style="background-color: #fee087">QTc-prolonging medications</span>.
            Evelyn would like to know the <span style="background-color: #a8a8a8">likelihood of </span><span style="background-color: #f6bf8b">clinically
              significant QTc prolongation</span> due to a brief course of co-administration of fluoxetine
            and ondansetron, and if there is a <span style="background-color: #dfa99f">recommendation for dose adjustment or an alternate antiemetic</span>.</li>
        </ul>
        <p><strong>(Pediatrics) Azole antifungals + Tacrolimus</strong></p>
        <ul>
          <li>William is a pediatric hospitalist caring for a child with a history of liver transplant
            due to congenital liver disease, treated with tacrolimus to prevent organ rejection.
            The patient is admitted with a fever and starts broad anti-infective therapy, including
            vancomycin, piperacillin-tazobactam and fluconazole.  William knows that azole antifungals
            can increase tacrolimus levels and wants to know if there is <span style="background-color: #bed1f6">evidence</span>
            to guide a <span style="background-color: #dfa99f">decrease the patient’s tacrolimus dose</span> to prevent
            <span style="background-color: #fee087">tacrolimus toxicity</span>. He additionally wants to
            know the <span style="background-color: #a9d098">mechanism of interaction</span> to
            <span style="background-color: #dfa99f">avoid further interacting medications</span>.</li>
        </ul>
      </section>
      <section id="eval-management-options-phys">
        <h2>Evaluation of Management Options for Drug-Drug Interactions, Physician</h2>
        <p><strong>Warfarin + Naproxen</strong></p>
        <ul>
          <li>Melissa is a family physician whose patient called because he is
            experiencing noticeable <span style="background-color: #fee087">bruising</span>.  Melissa knows that the patient is
            taking warfarin, but he has not experienced bruising before.  She asks if
            the patient has taken any new medications recently, and he mentions that
            he visited a pain clinic for his chronic back pain and they prescribed the
            NSAID naproxen.  Melissa knows that NSAIDs can <span style="background-color: #fee087">increase the risk of bleeding</span>
            when taken with warfarin, and she wants to know the <span style="background-color: #dfa99f">best way to manage this interaction</span>.</li>
        </ul>
      </section>
      <section id="eval-management-options-pharm">
        <h2>Evaluation of Management Options for Drug-Drug Interactions, Pharmacist</h2>
        <p><strong>Atorvastatin + Clarithromycin</strong></p>
        <ul>
          <li>James is a community pharmacist reviewing an electronic prescription
            that just came in for clarithromycin; an alert in his pharmacy’s
            information system indicates that there is a potential interaction
            between the clarithromycin and the atorvastatin that the patient was
            prescribed a year ago by different physician.  James calls the patient
            in order to discuss her medications; she tells him that she is taking
            the atorvastatin as prescribed, and cannot remember if she has ever taken
            clarithromycin in the past.  In preparation for following up with the patient’s
            physician, James would like to know the <span style="background-color: #a8a8a8">likelihood of an adverse drug event</span>
            such as <span style="background-color: #fee087">rhabdomyolysis</span>
            occurring due to a potential interaction and <span style="background-color: #f6bf8b">how serious
              the interaction could be</span>.  He would also like to know if <span style="background-color: #dfa99f">monitoring would be
              appropriate for this patient, or if a dose adjustment or temporary discontinuation
              of one of the drugs</span> would be best.</li>
        </ul>
      </section>
      <section id="nurse-screening">
        <h2>Screening for Drug-Drug Interactions, Nurse</h2>
        <p><strong>Glipizide + Lisinopril (Sulfonylureas + ACE Inhibitors)</strong></p>
        <ul>
          <li>Nancy is a licensed practice nurse who works in a skilled nursing facility.
            She has noticed that her patient is experiencing symptoms of
            <span style="background-color: #fee087">hypoglycemia</span>.
            She sees that the patient was recently prescribed lisinopril, and is wondering
            if it interacts with one of the five medications that she is taking.
            Nancy remembers reading about a potential interaction with the glipizide
            that the patient is currently taking.  She would like to know <span style="background-color: #fee087">if the
              patient’s symptoms are a possible consequence of an interaction</span> between
            the glipizide and the lisinopril, or the lisinopril and one of the other
            medications that the patient is taking, and if so, <span style="background-color: #dfa99f">what information she
              should pass along to the registered nurse in charge in order to help
              treat the patient</span>.</li>
        </ul>
      </section>
      <section id="editor-synthesis-dissemination">
        <h2>Synthesis for Dissemination, Drug Compendium Editor</h2>
        <p><strong>Tyrosine Kinase Inhibitors + Proton Pump Inhibitors</strong></p>
        <ul>
          <li>Olivia is a drug compendium editor who is reviewing the available
            literature for the potential interaction between tyrosine kinase
            inhibitors and proton pump inhibitors.  She would like to review
            the most recent literature available surrounding the interaction,
            and would like to compare it against the existing entry in her drug
            compendium.  She would like to understand more about the <span style="background-color: #a9d098">mechanism
              of the interaction</span>, whether it applies to all drugs within the classes,
            <span style="background-color: #d0c7e3">whether certain populations are at greater risk</span>, and the types and
            strength of the <span style="background-color: #bed1f6">evidence</span> available.  She would also like to learn
            more about <span style="background-color: #dfa99f">recommended management options</span>.</li>
        </ul>
      </section>
      <section id="librarian-dissemination"> 
        <h2>Synthesis for Dissemination, Librarian</h2>
        <ul>
          <li>Michael is a librarian who works for the medication safety unit in a regulatory
            agency.  He has graduate training in library and information science, and
            has a good understanding of medical reference sources.  When he is asked
            to locate information about a potential drug-drug interaction, he wants to
            understand more about the terms used to describe the drugs so that he can
            develop search strategies to run daily, weekly, and monthly searches.
            He would like to find terms used to describe the specific drugs involved
            in the interaction, drug class concepts, <span style="background-color: #fee087">clinical consequences</span> of the
            interaction, and existing types of <span style="background-color: #bed1f6">evidence</span> of the interaction.</li>
        </ul>
      </section>
      <section id="cds-team">
        <h2>Synthesis for Dissemination, Clinical Decision Support Team - Systems Analyst & Content Specialist</h2>
        <ul>
          <li>Richard is a systems analyst who is working with Joe, a content
            specialist, in order to design a new clinical information system
            which can provide personalized clinical knowledge and patient information
            for clinicians to improve healthcare quality. Richard is professionally
            trained in algorithms, databases, and programming. He also has some
            knowledge about electronic medical records. In order to help Richard
            design and implement the system, Joe would like to know about the
            <span style="background-color: #bed1f6">evidence</span>,
            <span style="background-color: #fee087">clinical consequences</span>, and
            <span style="background-color: #a9d098">mechanisms of interactions</span> of
            potential drug-drug interactions so that he can develop rules for
            the most clinically relevant interactions. With that information,
            he can help Richard create linkages and designs algorithms based
            on electronic medical records. Joe can also help Richard prioritize
            what to display and how to display information or alerts for clinicians.</li>
        </ul>
      </section>
    <section id="out-of-scope-stories">
      <h2>Out of scope user stories</h2>
      <p>The following user stories were considered as outside of scope of the task of developing the PDDI minimum
	information model, since the goals of the user stories were to determine how healthcare providers use
	PDDI information in patient care, what PDDI resources healthcare providers use when making patient care
	decisions, and how those PDDI resources are developed.</p>
      <p>Synthesis for Dissemination, Clinical Decision Support User Interface Designer<br>
	Synthesis for Dissemination, Data Scientist<br>
	Population Management, Pharmacoepidemiologist<br>
	Population Management, Insurance Companies<br>
	Population Management, P&T Committee (Formulary Development)<br>
	Population Management, Med Safety Department (Pharmaceutical Industry)<br>
	Passive Role, Patient</p>
    </section>    
  </section>


    </section>


  <section id="kr-process-apdx">
    <h2>Definition of guidelines for knowledge representation</h2>
    
    <font color="grey">A sub-team of the task force focused on setting the scope of
    knowledge representation for the minimum information model. A
    series of teleconferences bringing together domain experts,
    biomedical informatics specialists, and knowledge representation
    experts across the task force. Starting with a core set of
    questions, topics were discussed, arguments for different
    approaches were laid out and, agreement among the participants was
    sought. Besides the conversation during the teleconferences,
    participants had the opportunity to add comments and voice their
    opinion to the statements in the document. When the task force
    arrived at a consolidated version, the group voted by
    teleconference and through e-mail. The result of that vote was
    written into a draft document. The final version of the document
    was revised and written as Section <a href=""#KR-discussion""></a>
      of this document.
      </font>
  </section>
  </section>
  
  <section id="Value-Sets">
    <h2>Value Sets to Support PDDI Examples</h2>

    <section id="aldosterone-antagonists">
      <h2>aldosterone antagonists (RxNorm)</h2>
      <pre>
	298869 - eplerenone
	9997 - Spironolactone
	351256 - eplerenone 25 MG Oral Tablet
	351257 - eplerenone 50 MG Oral Tablet
	198224 - Hydrochlorothiazide 25 MG / Spironolactone 25 MG Oral Tablet
	198225 - Hydrochlorothiazide 50 MG / Spironolactone 50 MG Oral Tablet
	198222 - Spironolactone 100 MG Oral Tablet
	313096 - Spironolactone 25 MG Oral Tablet
	198223 - Spironolactone 50 MG Oral Tablet
      </pre>	    
    </section>

    <section id="bosutinib">
      <h2>bosutinib (ATC)</h2>
      <pre>
	L01XE14 - bosutinib
      </pre>	    
    </section>

    
    <section id="cereb-hemm">
      <h2>cerebral hemorrhage (ICD-10)</h2>
      <pre>
	I61.0 - Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
	I61.1 - Nontraumatic intracerebral hemorrhage in hemisphere, cortical
	I61.2 - Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
	I61.3 - Nontraumatic intracerebral hemorrhage in brain stem
	I61.4 - Nontraumatic intracerebral hemorrhage in cerebellum
	I61.5 - Nontraumatic intracerebral hemorrhage, intraventricular
	I61.6 - Nontraumatic intracerebral hemorrhage, multiple localized
	I61.8 - Other nontraumatic intracerebral hemorrhage
	I61.9 - Nontraumatic intracerebral hemorrhage, unspecified
	P10.0 - Subdural hemorrhage due to birth injury
	P10.1 - Cerebral hemorrhage due to birth injury
	P10.2 - Intraventricular hemorrhage due to birth injury
	P10.3 - Subarachnoid hemorrhage due to birth injury
	P10.4 - Tentorial tear due to birth injury
	P10.8 - Other intracranial lacerations and hemorrhages due to birth injury
	P10.9 - Unspecified intracranial laceration and hemorrhage due to birth injury
	P52.0 - Intraventricular (nontraumatic) hemorrhage, grade 1, of newborn
	P52.1 - Intraventricular (nontraumatic) hemorrhage, grade 2, of newborn
	P52.2 - Intraventricular (nontraumatic) hemorrhage, grade 3 and grade 4, of newborn
	P52.3 - Unspecified intraventricular (nontraumatic) hemorrhage of newborn
	P52.4 - Intracerebral (nontraumatic) hemorrhage of newborn
	P52.5 - Subarachnoid (nontraumatic) hemorrhage of newborn
	P52.6 - Cerebellar (nontraumatic) and posterior fossa hemorrhage of newborn
	P52.8 - Other intracranial (nontraumatic) hemorrhages of newborn
	P52.9 - Intracranial (nontraumatic) hemorrhage of newborn, unspecified
	S06.8 - Other specified intracranial injuries
      </pre>	    
    </section>

    <section id="acml">
      <h2>chronic myeloid leukemia (SNOMED-CT)</h2>
      <pre>
	415287001 - Relapsing chronic myeloid leukemia
	277589003 - Atypical chronic myeloid leukemia
	277587001 - Juvenile chronic myeloid leukemia
	128826001 - Atypical chronic myeloid leukemia, BCR/ABL negative
      </pre>
    </section>

    <section id="dasatinib">
      <h2>dasatinib (ATC)</h2>
      <pre>
	L01XE06 - dasatinib
      </pre>	    
    </section>


    
    <section id="gi-bleeding">
      <h2>gastrointestinal bleeding or peptic ulcer (ICD-10)</h2>
      <pre>
	k92.2 – Gastrointestinal hemorrhage, unspecified
	k25.0 – Acute gastric ulcer with hemorrhage
	k25.2 – Acute gastric ulcer with hemorrhage and perforation
	k25.4 – Chronic or unspecified gastric ulcer with hemorrhage
	k25.6 – Chronic or unspecified gastric ulcer with both hemorrhage and perforation
	k26.0 – Acute duodenal ulcer with hemorrhage
	k26.2 - Acute duodenal ulcer with hemorrhage and perforation
	k26.4 – Chronic duodenal ulcer with hemorrhage
	k26.6 – Chronic duodenal ulcer with hemorrhage and perforation
	k27.0 – Acute peptic ulcer, site unspecified, with hemorrhage
	k27.2 - Acute peptic ulcer, site unspecified, with hemorrhage and perforation
	k27.4 – Chronic peptic ulcer, site unspecified, with hemorrhage
	k27.6 – Chronic peptic ulcer, site unspecified, with hemorrhage and perforation
	k28.0 – Acute gastrojejunel ulcer with hemorrhage
	k28.2 - Acute gastrojejunel ulcer with hemorrhage and perforation
	k28.4 – Chronic gastrojejunel ulcer with hemorrhage
	k28.6 – Chronic Acute gastrojejunel ulcer with hemorrhage and perforation
	k29.01 – Acute gastritis with bleeding
	k29.31 – Chronic gastritis with bleeding
	k29.41 – Chronic atrophic gastritis with bleeding
	k29.51 – Unspecified chronic gastritis with bleeding
	k29.61 – Other gastritis with bleeding
	k29.71 – Gastritis, unspecified, with bleeding
	k29.81 – Duodenitis with bleeding
	k29.91 – Gastroduodenitis, unspecified, with bleeding
	k31.811 – Angiodysplasia –of stomach and duodenum with bleeding
	k31.82 – Dieulafoy lesion (hemorrhagic) of stomach and duodenum
      </pre>
    </section>

    <section id="imatinib">
      <h2>imatinib (ATC)</h2>
      <pre>
	L01XE01 - imatinib
      </pre>	    
    </section>

    
    <section id="icran-hemm">
      <h2>intracranial hemorrhage (ICD-10)</h2>
      <pre>
	I62.0 - Nontraumatic subdural hemorrhage
	I62.1 - Nontraumatic extradural hemorrhage
	I62.9 - Nontraumatic intracranial hemorrhage, unspecified
	I69.2 - Sequelae of other nontraumatic intracranial hemorrhage
	P10.0 - Subdural hemorrhage due to birth injury
	P10.1 - Cerebral hemorrhage due to birth injury
	P10.2 - Intraventricular hemorrhage due to birth injury
	P10.3 - Subarachnoid hemorrhage due to birth injury
	P10.4 - Tentorial tear due to birth injury
	P10.8 - Other intracranial lacerations and hemorrhages due to birth injury
	P10.9 - Unspecified intracranial laceration and hemorrhage due to birth injury
	P52.0 - Intraventricular (nontraumatic) hemorrhage, grade 1, of newborn
	P52.1 - Intraventricular (nontraumatic) hemorrhage, grade 2, of newborn
	P52.2 - Intraventricular (nontraumatic) hemorrhage, grade 3 and grade 4, of newborn
	P52.3 - Unspecified intraventricular (nontraumatic) hemorrhage of newborn
	P52.4 - Intracerebral (nontraumatic) hemorrhage of newborn
	P52.5 - Subarachnoid (nontraumatic) hemorrhage of newborn
	P52.6 - Cerebellar (nontraumatic) and posterior fossa hemorrhage of newborn
	P52.8 - Other intracranial (nontraumatic) hemorrhages of newborn
	P52.9 - Intracranial (nontraumatic) hemorrhage of newborn, unspecified
	S06.5 - Traumatic subdural hemorrhage
	S06.8 - Other specified intracranial injuries
      </pre>	    
    </section>

    <section id="misoprostol">
      <h2>misoprostol (RxNorm)</h2>
      <pre>
	42331 -  Misoprostol
      </pre>	    
    </section>

    <section id="nilotinib">
      <h2>nilotinib (ATC)</h2>
      <pre>
	L01XE08 - nilotinib
      </pre>	    
    </section>

    
    <section id="NSAIDS-drugs">
      <h2>non-steroidal anti-inflammatory drugs (NSAIDs) (RxNorm)</h2>
      <pre>
	1425 - Benzydamine
	140587 - celecoxib
	3355 - Diclofenac
	24605 - Etodolac
	24830 - fenbufen
	4331 - Fenoprofen
	4502 - Flurbiprofen
	5640 - Ibuprofen
	5781 - Indomethacin
	6142 - Ketoprofen
	35827 - Ketorolac
	588003 - Meclofenamate
	41493 - meloxicam
	31448 - nabumetone
	7258 - Naproxen
	32613 - oxaprozin
	8356 - Piroxicam
	10237 - Sulindac
	10255 - Suprofen
	37790 - tenoxicam
	10636 - Tolmetin
	278567 - valdecoxib
	1665675 - 1 ML Ketorolac Tromethamine 15 MG/ML Cartridge
	860092 - 1 ML Ketorolac Tromethamine 15 MG/ML Injection
	860113 - 1 ML Ketorolac Tromethamine 15 MG/ML Prefilled Syringe
	1665679 - 1 ML Ketorolac Tromethamine 30 MG/ML Cartridge
	1665461 - 1 ML Ketorolac Tromethamine 30 MG/ML Injection
	860114 - 1 ML Ketorolac Tromethamine 30 MG/ML Prefilled Syringe
	1367426 - 12 HR Naproxen sodium 220 MG / Pseudoephedrine Hydrochloride 120 MG Extended Release Oral Tablet
	1665682 - 2 ML Ketorolac Tromethamine 30 MG/ML Cartridge
	1665459 - 2 ML Ketorolac Tromethamine 30 MG/ML Injection
	860115 - 2 ML Ketorolac Tromethamine 30 MG/ML Prefilled Syringe
	855657 - 24 HR Diclofenac Sodium 100 MG Extended Release Oral Tablet
	310245 - 24 HR Etodolac 400 MG Extended Release Oral Tablet
	359500 - 24 HR Etodolac 500 MG Extended Release Oral Tablet
	310247 - 24 HR Etodolac 600 MG Extended Release Oral Tablet
	314059 - 24 HR Ketoprofen 100 MG Extended Release Oral Capsule
	311230 - 24 HR Ketoprofen 150 MG Extended Release Oral Capsule
	359697 - 24 HR Ketoprofen 200 MG Extended Release Oral Capsule
	433845 - 24 HR Naproxen 1000 MG Extended Release Oral Tablet
	1116320 - 24 HR Naproxen 375 MG Extended Release Oral Tablet
	1116339 - 24 HR Naproxen 500 MG Extended Release Oral Tablet
	1116349 - 24 HR Naproxen 750 MG Extended Release Oral Tablet
	992420 - 8 ACTUAT Ketorolac Tromethamine 15.8 MG/ACTUAT Nasal Inhaler
	1236089 - Benzydamine Hydrochloride 3 MG Oral Lozenge
	205322 - celecoxib 100 MG Oral Capsule
	205323 - celecoxib 200 MG Oral Capsule
	349514 - celecoxib 400 MG Oral Capsule
	686379 - celecoxib 50 MG Oral Capsule
	1297390 - Chlorpheniramine Maleate 2 MG / Ibuprofen 200 MG / Pseudoephedrine Hydrochloride 30 MG Oral Tablet
	1310503 - Chlorpheniramine Maleate 4 MG / Ibuprofen 200 MG / Phenylephrine Hydrochloride 10 MG Oral Tablet
	1442116 - Diclofenac 18 MG Oral Capsule
	1442128 - Diclofenac 35 MG Oral Capsule
	859063 - Diclofenac Potassium 1.67 MG/ML Oral Solution
	858342 - Diclofenac Potassium 25 MG Oral Capsule
	857702 - Diclofenac Potassium 25 MG Oral Tablet
	855942 - Diclofenac Potassium 50 MG Oral Tablet
	855633 - Diclofenac Sodium 0.01 MG/MG Topical Gel
	855642 - Diclofenac Sodium 0.03 MG/MG Topical Gel
	1234493 - Diclofenac Sodium 100 MG Oral Capsule
	857696 - Diclofenac Sodium 100 MG Rectal Suppository
	857698 - Diclofenac Sodium 12.5 MG Rectal Suppository
	855664 - Diclofenac Sodium 25 MG Delayed Release Oral Tablet
	857703 - Diclofenac Sodium 25 MG Rectal Suppository
	1599787 - Diclofenac Sodium 37.5 MG/ML Injectable Solution
	857706 - Diclofenac Sodium 50 MG / Misoprostol 0.2 MG Oral Tablet
	855906 - Diclofenac Sodium 50 MG Delayed Release Oral Tablet
	857709 - Diclofenac Sodium 50 MG Rectal Suppository
	1359105 - Diclofenac Sodium 75 MG / Misoprostol 0.2 MG Oral Tablet
	855926 - Diclofenac Sodium 75 MG Delayed Release Oral Tablet
	895664 - Diphenhydramine Citrate 38 MG / Ibuprofen 200 MG Oral Tablet
	901814 - Diphenhydramine Hydrochloride 25 MG / Ibuprofen 200 MG Oral Capsule
	1550957 - Diphenhydramine Hydrochloride 25 MG / Naproxen sodium 220 MG Oral Tablet
	994005 - Esomeprazole 20 MG / Naproxen 375 MG Delayed Release Oral Tablet
	994008 - Esomeprazole 20 MG / Naproxen 500 MG Delayed Release Oral Tablet
	197684 - Etodolac 200 MG Oral Capsule
	197685 - Etodolac 300 MG Oral Capsule
	197686 - Etodolac 400 MG Oral Tablet
	199390 - Etodolac 500 MG Oral Tablet
	1100066 - Famotidine 26.6 MG / Ibuprofen 800 MG Oral Tablet
	199740 - fenbufen 450 MG Oral Tablet
	197694 - Fenoprofen 200 MG Oral Capsule
	858116 - Fenoprofen 400 MG Oral Capsule
	310291 - Fenoprofen 600 MG Oral Tablet
	197724 - Flurbiprofen 100 MG Oral Tablet
	199749 - Flurbiprofen 200 MG Extended Release Oral Capsule
	197725 - Flurbiprofen 50 MG Oral Tablet
	859315 - Hydrocodone Bitartrate 10 MG / Ibuprofen 200 MG Oral Tablet
	858770 - Hydrocodone Bitartrate 2.5 MG / Ibuprofen 200 MG Oral Tablet
	858778 - Hydrocodone Bitartrate 5 MG / Ibuprofen 200 MG Oral Tablet
	858798 - Hydrocodone Bitartrate 7.5 MG / Ibuprofen 200 MG Oral Tablet
	310963 - Ibuprofen 100 MG Chewable Tablet
	198405 - Ibuprofen 100 MG Oral Tablet
	854183 - Ibuprofen 100 MG/ML Injectable Solution
	1310487 - Ibuprofen 20 MG/ML / Pseudoephedrine Hydrochloride 3 MG/ML Oral Suspension
	197803 - Ibuprofen 20 MG/ML Oral Suspension
	1369775 - Ibuprofen 200 MG / Phenylephrine Hydrochloride 10 MG Oral Tablet
	1299018 - Ibuprofen 200 MG / Pseudoephedrine Hydrochloride 30 MG Oral Capsule
	1299021 - Ibuprofen 200 MG / Pseudoephedrine Hydrochloride 30 MG Oral Tablet
	310964 - Ibuprofen 200 MG Oral Capsule
	310965 - Ibuprofen 200 MG Oral Tablet
	204442 - Ibuprofen 40 MG/ML Oral Suspension
	1049589 - Ibuprofen 400 MG / Oxycodone Hydrochloride 5 MG Oral Tablet
	197805 - Ibuprofen 400 MG Oral Tablet
	197806 - Ibuprofen 600 MG Oral Tablet
	197807 - Ibuprofen 800 MG Oral Tablet
	346508 - Indomethacin 1 MG/ML Injectable Solution
	199549 - Indomethacin 100 MG Rectal Suppository
	1490727 - Indomethacin 20 MG Oral Capsule
	197817 - Indomethacin 25 MG Oral Capsule
	1491529 - Indomethacin 40 MG Oral Capsule
	310991 - Indomethacin 5 MG/ML Oral Suspension
	197818 - Indomethacin 50 MG Oral Capsule
	197819 - Indomethacin 50 MG Rectal Suppository
	310992 - Indomethacin 75 MG Extended Release Oral Capsule
	199321 - Ketoprofen 100 MG Oral Capsule
	249482 - Ketoprofen 100 MG Oral Tablet
	199553 - Ketoprofen 100 MG Rectal Suppository
	431823 - Ketoprofen 150 MG Extended Release Oral Tablet
	429192 - Ketoprofen 25 MG Oral Tablet
	197855 - Ketoprofen 50 MG Oral Capsule
	247630 - Ketoprofen 50 MG Rectal Suppository
	197856 - Ketoprofen 75 MG Oral Capsule
	834022 - Ketorolac Tromethamine 10 MG Oral Tablet
	860096 - Ketorolac Tromethamine 30 MG/ML Injectable Solution
	618552 - Meclofenamate 100 MG Oral Capsule
	618557 - Meclofenamate 50 MG Oral Capsule
	597406 - meloxicam 1.5 MG/ML Oral Suspension
	152695 - meloxicam 15 MG Oral Tablet
	311486 - meloxicam 7.5 MG Oral Tablet
	311892 - nabumetone 500 MG Oral Tablet
	311893 - nabumetone 750 MG Oral Tablet
	245420 - Naproxen 125 MG Oral Tablet
	311913 - Naproxen 25 MG/ML Oral Suspension
	198013 - Naproxen 250 MG Oral Tablet
	603103 - Naproxen 375 MG Delayed Release Oral Tablet
	198012 - Naproxen 375 MG Oral Tablet
	311915 - Naproxen 500 MG Delayed Release Oral Tablet
	198014 - Naproxen 500 MG Oral Tablet
	199490 - Naproxen 500 MG Rectal Suppository
	1112231 - Naproxen sodium 220 MG Oral Capsule
	849574 - Naproxen sodium 220 MG Oral Tablet
	849398 - Naproxen sodium 275 MG Oral Tablet
	849450 - Naproxen sodium 500 MG / Sumatriptan 85 MG Oral Tablet
	849431 - Naproxen sodium 550 MG Oral Tablet
	1653765 - Naproxen sodium 60 MG / Sumatriptan 10 MG Oral Tablet
	312132 - oxaprozin 600 MG Oral Tablet
	198107 - Piroxicam 10 MG Oral Capsule
	199559 - Piroxicam 10 MG Oral Tablet
	247066 - Piroxicam 10 MG Rectal Suppository
	198108 - Piroxicam 20 MG Oral Capsule
	199560 - Piroxicam 20 MG Oral Tablet
	105942 - Piroxicam 20 MG Rectal Suppository
	199279 - Sulindac 100 MG Oral Tablet
	198238 - Sulindac 150 MG Oral Tablet
	198239 - Sulindac 200 MG Oral Tablet
	199516 - tenoxicam 10 MG Oral Tablet
	105954 - tenoxicam 20 MG Oral Tablet
	250197 - tenoxicam 20 MG Rectal Suppository
	198295 - Tolmetin 200 MG Oral Tablet
	198296 - Tolmetin 400 MG Oral Capsule
	198297 - Tolmetin 600 MG Oral Tablet
	349319 - valdecoxib 10 MG Oral Tablet
	349321 - valdecoxib 20 MG Oral Tablet	      
      </pre>	    
    </section>


    <section id="ponatinib">
      <h2>ponatinib (ATC)</h2>
      <pre>
	L01XE24 - ponatinib
      </pre>	    
    </section>

    
    <section id="proton-pump-inhibitor-atc">
      <h2>proton pump inhibitor (ATC)</h2>
      <pre>
	A02BC06 - dexlansoprazole
	A02BC05 - esomeprazole
	A02BC03 - lansoprazole
	A02BC01 - omeprazole
	A02BC02 - pantoprazole
	A02BC04 - rabeprazole
      </pre>	    
    </section>

    
    <section id="proton-pump-inhibitor">
      <h2>proton pump inhibitor (RxNorm)</h2>
      <pre>
	816346 -  Dexlansoprazole
	283742 -   Esomeprazole
	17128 -  Lansoprazole
	7646 -  Omeprazole
	40790 -  Pantoprazole
	114979 -  Rabeprazole		
      </pre>	    
    </section>


    
    <section id="systemic-cortico">
      <h2>systemic corticosteroids (RxNorm)</h2>
      <pre>
	1514 - Betamethasone
	2878 - Cortisone
	3264 - Dexamethasone
	4452 - Fludrocortisone
	5492 - Hydrocortisone
	6902 - Methylprednisolone
	8638 - prednisolone
	8640 - Prednisone
	10759 - Triamcinolone
	1085795 - 100 ACTUAT Triamcinolone Acetonide 0.055 MG/ACTUAT Nasal Inhaler
	833245 - 120 ACTUAT Triamcinolone Acetonide 0.05 MG/ACTUAT Nasal Inhaler
	1085798 - 120 ACTUAT Triamcinolone Acetonide 0.055 MG/ACTUAT Nasal Inhaler
	1493473 - 60 ACTUAT Triamcinolone Acetonide 0.055 MG/ACTUAT Nasal Inhaler
	670084 - Betamethasone 0.12 MG/ML Oral Solution
	308709 - Betamethasone 0.6 MG Oral Tablet
	578803 - Betamethasone 3 MG/ML / Betamethasone acetate 3 MG/ML Injectable Suspension
	197543 - Cortisone 10 MG Oral Tablet
	197545 - Cortisone 5 MG Oral Tablet
	828248 - cortisone acetate 25 MG Oral Tablet
	309686 - Dexamethasone 0.1 MG/ML Oral Solution
	197577 - Dexamethasone 0.5 MG Oral Tablet
	854177 - Dexamethasone 0.7 MG Drug Implant
	343033 - Dexamethasone 0.75 MG Oral Tablet
	197579 - Dexamethasone 1 MG Oral Tablet
	309684 - Dexamethasone 1 MG/ML Oral Solution
	197580 - Dexamethasone 1.5 MG Oral Tablet
	309696 - Dexamethasone 10 MG/ML Injectable Solution
	197581 - Dexamethasone 2 MG Oral Tablet
	197582 - Dexamethasone 4 MG Oral Tablet
	197583 - Dexamethasone 6 MG Oral Tablet
	1116927 - Dexamethasone phosphate 4 MG/ML Injectable Solution
	313979 - Fludrocortisone 0.1 MG Oral Tablet
	260192 - Hydrocortisone 0.01 MG/MG Rectal Ointment
	310878 - Hydrocortisone 1.67 MG/ML Enema
	197782 - Hydrocortisone 10 MG Oral Tablet
	310868 - Hydrocortisone 10 MG/ML Rectal Cream
	1494032 - Hydrocortisone 10 MG/ML Vaginal Cream
	310899 - Hydrocortisone 2 MG/ML Oral Suspension
	197783 - Hydrocortisone 20 MG Oral Tablet
	1246528 - Hydrocortisone 25 MG/ML / Pramoxine hydrochloride 10 MG/ML Rectal Cream
	310879 - Hydrocortisone 25 MG/ML Rectal Cream
	199320 - Hydrocortisone 4 MG Oral Tablet
	197787 - Hydrocortisone 5 MG Oral Tablet
	238755 - Hydrocortisone 50 MG/ML Injectable Solution
	1012221 - hydrocortisone acetate 0.0055 MG/MG / Lidocaine Hydrochloride 0.028 MG/MG Rectal Gel
	1012223 - hydrocortisone acetate 0.025 MG/MG / Lidocaine Hydrochloride 0.03 MG/MG Rectal Gel
	1012229 - hydrocortisone acetate 10 MG/ML / Lidocaine Hydrochloride 30 MG/ML Rectal Cream
	1235049 - hydrocortisone acetate 10 MG/ML / Pramoxine hydrochloride 10 MG/ML Rectal Cream
	828362 - hydrocortisone acetate 10 MG/ML / Pramoxine hydrochloride 10 MG/ML Rectal Foam
	1545172 - hydrocortisone acetate 100 MG/ML Rectal Foam
	1114854 - hydrocortisone acetate 18.5 MG/ML / Pramoxine hydrochloride 11.5 MG/ML Rectal Cream
	1012233 - hydrocortisone acetate 20 MG/ML / Lidocaine Hydrochloride 20 MG/ML Rectal Cream
	1094443 - hydrocortisone acetate 23.5 MG/ML / Pramoxine hydrochloride 10 MG/ML Rectal Cream
	1291082 - hydrocortisone acetate 25 MG Rectal Suppository
	1294025 - hydrocortisone acetate 25 MG/ML / Pramoxine hydrochloride 10 MG/ML Rectal Cream
	1291085 - hydrocortisone acetate 30 MG Rectal Suppository
	1012235 - hydrocortisone acetate 5 MG/ML / Lidocaine Hydrochloride 30 MG/ML Rectal Cream
	199771 - Methylprednisolone 100 MG Oral Tablet
	328161 - Methylprednisolone 16 MG Oral Tablet
	197969 - Methylprednisolone 2 MG Oral Tablet
	197970 - Methylprednisolone 24 MG Oral Tablet
	197971 - Methylprednisolone 32 MG Oral Tablet
	259966 - Methylprednisolone 4 MG Oral Tablet
	311659 - Methylprednisolone 40 MG/ML Injectable Solution
	314099 - Methylprednisolone 62.5 MG/ML Injectable Solution
	1357886 - Methylprednisolone 65.4 MG/ML Injectable Solution
	197973 - Methylprednisolone 8 MG Oral Tablet
	1358510 - methylprednisolone acetate 20 MG/ML Injectable Suspension
	1358610 - methylprednisolone acetate 40 MG/ML Injectable Suspension
	1358617 - methylprednisolone acetate 80 MG/ML Injectable Suspension
	199343 - prednisolone 1 MG Oral Tablet
	312614 - prednisolone 1 MG/ML Oral Solution
	643123 - prednisolone 10 MG Disintegrating Oral Tablet
	643125 - prednisolone 15 MG Disintegrating Oral Tablet
	794979 - prednisolone 2 MG/ML Oral Solution
	429199 - prednisolone 20 MG Oral Tablet
	199967 - prednisolone 25 MG Oral Tablet
	283077 - prednisolone 3 MG/ML Oral Solution
	793099 - prednisolone 3 MG/ML Oral Suspension
	643127 - prednisolone 30 MG Disintegrating Oral Tablet
	702306 - prednisolone 4 MG/ML Oral Solution
	198142 - prednisolone 5 MG Oral Tablet
	249066 - prednisolone 5 MG/ML Oral Solution
	1303125 - Prednisone 1 MG Delayed Release Oral Tablet
	198144 - Prednisone 1 MG Oral Tablet
	315187 - Prednisone 1 MG/ML Oral Solution
	198145 - Prednisone 10 MG Oral Tablet
	1303132 - Prednisone 2 MG Delayed Release Oral Tablet
	198146 - Prednisone 2.5 MG Oral Tablet
	312615 - Prednisone 20 MG Oral Tablet
	1303135 - Prednisone 5 MG Delayed Release Oral Tablet
	312617 - Prednisone 5 MG Oral Tablet
	205301 - Prednisone 5 MG/ML Oral Solution
	198148 - Prednisone 50 MG Oral Tablet
	198301 - Triamcinolone 1 MG Oral Tablet
	1085728 - Triamcinolone Acetonide 0.001 MG/MG Oral Paste
	1085750 - Triamcinolone Acetonide 10 MG/ML Injectable Suspension
	1085754 - Triamcinolone Acetonide 40 MG/ML Injectable Suspension
	1085996 - triamcinolone hexacetonide 20 MG/ML Injectable Suspension
	1085992 - triamcinolone hexacetonide 5 MG/ML Injectable Suspension
      </pre>	    
    </section>

    
    <section id="topical-diclof">
      <h2>topical diclofenac (RxNorm)</h2>
      <pre>
	1234735 - diclofenac epolamine 0.0129 MG/MG Topical Gel
      </pre>	    
    </section>

    <section id="TKIs">
      <h2>tyrosine kinase inhibitors (TKIs) (ATC)</h2>
      <pre>
	L01XE04 - sunitinib
	L01XC03 - trastuzumab
	L01XC14 - ado-trastuzumab emtansine
      </pre>	    
    </section>


    <section id="warfarins">
      <h2>warfarin (RxNorm)</h2>
      <pre>
	855288 - Warfarin Sodium 1 MG Oral Tablet
	855296 - Warfarin Sodium 10 MG Oral Tablet
	855302 - Warfarin Sodium 2 MG Oral Tablet
	855308 - Warfarin Sodium 2 MG/ML Injectable Solution
	855312 - Warfarin Sodium 2.5 MG Oral Tablet
	855318 - Warfarin Sodium 3 MG Oral Tablet
	855324 - Warfarin Sodium 4 MG Oral Tablet
	855332 - Warfarin Sodium 5 MG Oral Tablet
	855338 - Warfarin Sodium 6 MG Oral Tablet
	855344 - Warfarin Sodium 7.5 MG Oral Tablet
	11289 - Warfarin
      </pre>	    
    </section>
  </section>
  
  <section id="appendix-xml">
    <h2>Proposed XML Examples</h2>
    <p>The purpose of this note is to describe the content of
    the PDDI minimal information model, leaving representational
      issues to be resolved in an anticipated future note.
    Any eventual representation models will rely heavily on
    existing ontologies and relevant models such as FHIR
    [[bender-2013]][[mandel-2016]].  Specifically, as medications may be
    represented with a variety of codes, we propose using a
    representation similar to
    FHIR's <A HREF="https://www.hl7.org/fhir/datatypes.html#CodeableConcept">CodeableConcept</a>,
    which will allow for clear an unambiguous representation of
    medications thorugh reference to established vocabularies, without
    requiring the use of any single vocabulary.
								
    <p>Here, we present straw man XML representations of two example
    PDDIs.   As representational issues have not been
    fully resolved, these examples should be considered informative
    (not normative) and subject to revision.</p>

    <section>
      <h2>Example 1: warfarin and non-steroidal anti-inflammatory drugs (NSAIDs)</h2>
      <pre class="example" style="white-space: pre-wrap"
	   title="Warfarin and non-steroidal anti-inflammatory drugs
		  (NSAIDs)">

	&lt!--Note: Placeholder URIS for undefined PIO
	and other concepts to be replaced by once concepts are created.--&gt
	&ltMPIO:MPIO_00000xx label='drugs involved'&gt


	&ltDRON:DRON_00000005 label="drug product"&gt
	&ltcoding&gt
	&ltsystem&gt "http://www.nlm.nih.gov/research/umls/rxnorm"&lt/system&gt
	&ltcode&gt11289&lt/code&gt
	&ltdisplay&gtWARFARIN&lt/display&gt
	&lt/coding&gt

	&lt/DRON:DRON_00000005&gt

	&ltDRON:DRON_00000001 label="clinical drug role"&gt
	&ltcoding&gt
	&ltsystem&gt "http://www.nlm.nih.gov/research/umls/snomedct"&lt/system&gt
	&ltcode&gtC0003211&lt/code&gt
	&ltdisplay&gtAnti-inflammatory agents, Non-Steroidal&lt/display&gt
	&lt/coding&gt
	&lt/DRON:DRON_00000001&gt
	
	
	&lt/MPIO:MPIO_00000xx&gt

	&ltMPIO:MPIO_0000005 label=’mechanism of interaction information’&gt
	‘Non-steroidal anti-inflammatory drugs (NSAIDs) have antiplatelet effects which increase the bleeding risk when combined with oral anticoagulants such as warfarin. The antiplatelet effect of NSAIDs lasts only as long as the NSAID is present in the circulation, unlike aspirin’s antiplatelet effect, which lasts for up to 2 weeks after aspirin is discontinued. NSAIDs also can cause peptic ulcers and most of the evidence for increased bleeding risk with NSAIDs plus warfarin is due to upper gastrointestinal bleeding (UGIB).’
	&lt/MPIO:MPIO_0000005&gt

	&ltMPIO:MPIO_0000003
	label=’information about clinical consequences suspected to be the result of a drug-drug interaction’&gt ‘Increased risk of bleeding’
	&lt/MPIO:MPIO_0000003&gt

	&ltMPIO:MPIO_0000009 label=’seriousness’&gt
	‘Bleeding is a serious potential clinical consequence because it can result in death, life-threatening hospitalization, and disability.’
	&lt/MPIO:MPIO_0000009&gt

	&ltMPIO:MPIO_0000010 label=’severity’&gt
	‘The intensity of a bleeding event may vary’
	&lt/MPIO:MPIO_0000010&gt

	&ltMPIO:MPIO_0000008 label=’recommended action’&gt
	‘If the NSAID is being used as an analgesic or antipyretic, it would be prudent
	to use an alternative such as acetaminophen. In some people, acetaminophen can increase the anticoagulant effect of warfarin, so monitor the INR if acetaminophen is used in doses over 2 g/day for a few days. For more severe pain consider short-term opioids in place of the NSAID.’
	&lt/MPIO:MPIO_0000008&gt

	&ltMPIO:MPIO_0000007 label=’Frequency of Exposure to the PDDI’&gt
	‘Unknown’
	&ltMPIO:MPIO_0000007&gt

	&ltMPIO:MPIO_0000006 label=’Frequency of Harm for persons who have been exposed to the PDDI’&gt
	‘Unknown’
	&ltMPIO:MPIO_0000006&gt

	&ltMPIO:MPIO_0000000 label=’modifying factors information’ expressionLogic=’human readable’ conceptSets=’None’&gt
	&ltlistOfModifyingFactors&gt
	&ltit&gt
	‘The NSAID is topical diclofenac’
	&ltMPIO:MPIO_0000008 label=’recommended action’&gt
        ‘No special precautions’
	&lt/MPIO:MPIO_0000008&gt
	&ltMPIO:MPIO_0000004 label=’Evidence for a Suspected Drug-Drug Interaction’&gt
        ‘Topical diclofenac has relatively low systemic absorption; in one study a
	topical gel (16 g/day) produced about 6% of the absorption seen with systemic
	administration of 150 mg/day. A higher than recommended dose of topical gel
	(48 g/day) produced 20% of a systemic dose of diclofenac.’
	&lt/MPIO:MPIO_0000004&gt
	&lt/it&gt
	&ltit&gt
	‘The NSAID is NOT topical diclofenac but the patient is concomitantly taking a
	proton pump inhibitor or misoprostol’
	&ltMPIO:MPIO_0000008 label=’recommended action’&gt
        ‘Assess risk and take action if necessary’
	&lt/MPIO:MPIO_0000008&gt
	&ltMPIO:MPIO_0000004 label=’Evidence for a Suspected Drug-Drug Interaction’&gt
        ‘Proton pump inhibitors and misoprostol may reduce the risk of UGIB in
	patients receiving NSAIDs and warfarin.’
	&lt/MPIO:MPIO_0000004&gt
	&lt/it&gt
	&ltit&gt
	‘The NSAID is NOT topical diclofenac, the patient is NOT concomitantly taking a
	proton pump inhibitor or misoprostol, and the patient has one or more of the following risk factors: history of UGIB or peptic ulcer or &gt 65 years old’
	&ltMPIO:MPIO_0000008 label=’recommended action’&gt
        ‘Use only if benefit outweighs risk’
	&lt/MPIO:MPIO_0000008&gt
	&ltMPIO:MPIO_0000004 label=’Evidence for a Suspected Drug-Drug Interaction’&gt
        ‘Proton pump inhibitors and misoprostol may reduce the risk of UGIB in
	patients receiving NSAIDs and warfarin.’
	&lt/MPIO:MPIO_0000004&gt
	&lt/it&gt
	&ltit&gt
	‘The NSAID is NOT topical diclofenac, the patient is NOT concomitantly taking a
	proton pump inhibitor or misoprostol, and the patient has one or more of the following risk factors: concomitantly taking systemic corticosteroids, aldosterone antagonist, or high dose or multiple NSAIDs’
	&ltMPIO:MPIO_0000008 label=’recommended action’&gt
        ‘Use only if benefit outweighs risk’
	&lt/MPIO:MPIO_0000008&gt
	&ltMPIO:MPIO_0000004 label=’Evidence for a Suspected Drug-Drug Interaction’  references=’r1’&gt
	‘Both corticosteroids and aldosterone antagonists have been shown to substantially increase the risk of UGIB in patients on NSAIDs, with relative risks of 12.8 and 11 respectively compared to a risk of 4.3 with NSAIDs alone’
	&lt/MPIO:MPIO_0000004&gt
	&lt/it&gt
	&ltlistOfReferences&gt
	&ltreference id=’r1’&gt
	‘Masclee et al. Gastroenterology 2014;147:784-92.’
	&lt/reference&gt
	&lt/listOfReferences&gt
	&lt/MPIO:MPIO_0000000&gt

	&ltMPIO:MPIO_0000000 label=’modifying factors information’ expressionLogic=’CQL+FHIR’ conceptSets=’NLM Value Set Authority’&gt
	&lt![CDATA[
	library CMS146 version '2'

	/* CMS BOGUS RULE
	*
	* ============================================================================
	* QDM Logic
	* ============================================================================
	*
	* &ltLOGIC FOR DISTINGUISHING SITUATIONS WARRANTING 'No special precautions', 'Assess risk and take action if necessary.', AND 'Use only if benefit outweighs risk' GOES HERE&gt
	*
	* ============================================================================
	*/

	using FHIR

	valueset "warfarin": '&ltcode referencing that value set from National Library of Medicine Value Set Authority Center https://vsac.nlm.nih.gov/'
	valueset "topical diclofenac": '&ltcode referencing that value set from National Library of Medicine Value Set Authority Center https://vsac.nlm.nih.gov/'
	valueset "proton pump inhibitor": '&ltcode referencing that value set from National Library of Medicine Value Set Authority Center https://vsac.nlm.nih.gov/'
	&ltOTHER VALUE SETS REQUIRED TO IMPLEMENT THE CLINICAL LOGIC&gt

	&ltPARAMETERS AND DEFINITIONS REFERENCED IN THE QDM LOGIC&gt
	]]&gt
	&lt/MPIO:MPIO_0000000&gt
      </pre>
    </section>
    <section>
      <h2>Example 2: Tyrosine Kinase inhibitors and medications that increase gastric pH</h2>
      <pre class="example" style="white-space: pre-wrap"
	   title="Tyrosine Kinase inhibitors and medications that
		  increase gastric pH">


	&ltMPIO:MPIO_00000xx label='drugs involved'&gt



	&ltDRON:DRON_00000005 label="clinical drug role"&gt
	&ltcoding&gt
	&ltsystem&gt "http://www.nlm.nih.gov/research/umls/snomedct"&lt/system&gt
	&ltcode&gt C4521478 &lt/code&gt
	&ltdisplay&g Protein-tyrosine kinase inhibitor (disposition) &lt/display&gt
	&lt/coding&gt
	
	&lt/DRON:DRON_00000005&gt


	&ltDRON:DRON_00000005 label="clinical drug role"&gt
	&ltcoding&gt
	&ltsystem&gt TBD &lt/system&gt
	&ltcode&gt TBD &lt/code&gt
	&ltdisplay&g TBD &lt/display&gt
	&lt/coding&gt
	
	&lt/DRON:DRON_00000005&gt

	
	&lt/MPIO:MPIO_00000xx&gt

        &ltMPIO:MPIO_0000005 label=’mechanism of interaction information’&gt
	‘These TKIs demonstrate pH dependent absorption for oral administration which may result in decreased efficacy when given concomitantly with medications that increase gastric pH.’
	&lt/MPIO:MPIO_0000005&gt

	&ltMPIO:MPIO_0000003 label=’clinical consequences’&gt
	‘Decreased efficacy relative to treatment for chronic myeloid leukemia’
	&lt/MPIO:MPIO_0000003&gt

	&ltMPIO:MPIO_0000009 label=’seriousness’&gt
	‘A decrease in chronic myeloid leukemia treatment efficacy is a serious potential clinical consequence because it can result in death, life-threatening hospitalization, and disability.’
	&lt/MPIO:MPIO_0000009&gt

	&ltMPIO:MPIO_0000010 label=’severity’&gt
	‘There is no intensity scale relevant to describing a decrease in chronic myeloid leukemia treatment efficacy’
	&lt/MPIO:MPIO_0000010&gt

	&ltMPIO:MPIO_0000007 label=’Frequency of Exposure to the PDDI’&gt
	‘Unknown’
	&ltMPIO:MPIO_0000007&gt

	&ltMPIO:MPIO_0000006 label=’Frequency of Harm for persons who have been exposed to the PDDI’&gt
	‘Unknown’
	&ltMPIO:MPIO_0000006&gt

	&ltMPIO:MPIO_0000000 label=’modifying factors information’ expressionLogic=’human readable’ conceptSets=’None’&gt
	&ltlistOfModifyingFactors&gt
	&ltit&gt
	‘The TKI is imatinib or ponatinib’
	&ltMPIO:MPIO_0000008 label=’recommended action’&gt
        ‘No special precautions’
	&lt/MPIO:MPIO_0000008&gt
	&ltMPIO:MPIO_0000004 label=’Evidence for a Suspected Drug-Drug Interaction’ references=’r1,r2’&gt
        ‘Imatinib and ponatinib AUCs are not appreciably decreased by PPI
        co-administration.’
	&lt/MPIO:MPIO_0000004&gt
	&lt/it&gt
	&ltit&gt
	‘The TKI is nilotinib’
	&ltMPIO:MPIO_0000008 label=’recommended action’&gt
        ‘Assess risk and take action if necessary’
	&lt/MPIO:MPIO_0000008&gt
	&ltMPIO:MPIO_0000004 label=’Evidence for a Suspected Drug-Drug Interaction’ references=’r3’&gt
        ‘Bosutinib and nilotinib AUCs are decreased with concomitant PPIs but antacids
	and H2 antagonists may be considered if TKI is given 2 hours before the
	antacid/H2 antagonist. However, for nilotinib a retrospective study has
	shown no difference in cytogenetic response rates for patients taking PPIs.’
	&lt/MPIO:MPIO_0000004&gt
	&lt/it&gt
	&ltit&gt
	‘The TKI is bosutinib or dasatinib’
	&ltMPIO:MPIO_0000008 label=’recommended action’&gt
        ‘Use only if benefit outweighs risk’
	&lt/MPIO:MPIO_0000008&gt
	&ltMPIO:MPIO_0000004 label=’Evidence for a Suspected Drug-Drug Interaction’ references=’r4,r5’&gt
        ‘Bosutinib and nilotinib AUCs are decreased with concomitant PPIs but antacids
	and H2 antagonists may be considered if TKI is given 2 hours before the
  	antacid/H2 antagonist.’
	&lt/MPIO:MPIO_0000004&gt
	&lt/it&gt
	&ltlistOfReferences&gt
	&ltreference id=’r1’&gt
	‘Iclusig [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc. 2016’
	&lt/reference&gt
	&ltreference id=’r2’&gt
	‘Egorin MJ, Shah DD, Christner SM, et al. Effect of a proton pump inhibitor on
 	the pharmacokinetics of imatinib. Br J Clin Pharmacol. 2009;68(3):370-374.’
	&lt/reference&gt
	&ltreference id=’r3’&gt
	‘Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors
	or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350.’
	&lt/reference&gt
	&ltreference id=’r5’&gt
	‘Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015’
	&lt/reference&gt
	&ltreference id=’r6’&gt
	‘Bosulif [package insert]. New York, NY: Pfizer Labs; 2015.’
	&lt/reference&gt
	&lt/listOfReferences&gt
	&lt/MPIO:MPIO_0000000&gt

	&ltMPIO:MPIO_0000004 label=‘suspected drug-drug interaction evidence’&gt
	&ltlistOfEvidence&gt
	&ltit references=’r1’&gt
	‘Dasatinib area under the curve (AUC) is decreased when co-administered with antacids, H2 antagonists, and PPIs.’
	&lt/it&gt
	&ltit references=’r2,r3’&gt
	‘Bosutinib and nilotinib AUCs are decreased with concomitant PPIs but antacids and H2 antagonists may be considered if TKI is given 2 hours before the antacid/H2 antagonist.’
	&lt/it&gt
	&ltit references=’r4’&gt
	‘However, for nilotinib a retrospective study has shown no difference in cytogenetic response rates for patients taking PPIs.’
	&lt/it&gt
	&ltit references=’r5,r6’&gt
	‘Imatinib and ponatinib AUCs are not appreciably decreased by PPI co-administration.5,6’
	&lt/it&gt
	&lt/listOfEvidence&gt
	&ltlistOfReferences&gt
	&ltreference id=’r1’&gt
	‘Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015’
	&lt/reference&gt
	&ltreference id=’r2’&gt
	‘Bosulif [package insert]. New York, NY: Pfizer Labs; 2015.’
	&lt/reference&gt
	&ltreference id=’r3’&gt
	‘Tasigna [package insert]. East Hanover, NJ: Novartis; 2015.’
	&lt/reference&gt
	&ltreference id=’r4’&gt
	‘Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70(2):345-350.’
	&lt/reference&gt
	&ltreference id=’r5’&gt
	‘Iclusig [package insert]. Cambridge, MA: ARIAD Pharmaceuticals, Inc. 2016’
	&lt/reference&gt
	&ltreference id=’r6’&gt
	‘Egorin MJ, Shah DD, Christner SM, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol. 2009;68(3):370-374.’
	&lt/reference&gt
	&lt/listOfReferences&gt
	&lt/MPIO:MPIO_0000004&gt

	&ltMPIO:MPIO_0000000 label=’modifying factors information’ expressionLogic=’CQL+FHIR’ conceptSets=’NLM Value Set Authority’&gt
	&lt![CDATA[
   	library CMS146 version '2'

	/* CMS BOGUS RULE
	*
	* ============================================================================
	* QDM Logic
	* ============================================================================
	*
	* &ltLOGIC FOR DISTINGUISHING SITUATIONS WARRANTING 'No special precautions', 'Assess risk and take action if necessary.', AND 'Use only if benefit outweighs risk' GOES HERE&gt
	*
	* ============================================================================
	*/

	using FHIR

	valueset "Type of BCR-ABL Tyrosine Kinase Inhibitors": '&ltcode referencing that value set from National Library of Medicine Value Set Authority Center https://vsac.nlm.nih.gov/'
	valueset "Imatinib": '&ltcode referencing that value set from National Library of Medicine Value Set Authority Center https://vsac.nlm.nih.gov/'
	&ltOTHER VALUE SETS REQUIRED TO IMPLEMENT THE CLINICAL LOGIC&gt

	&ltPARAMETERS AND DEFINITIONS REFERENCED IN THE QDM LOGIC&gt
	]]&gt
	&lt/MPIO:MPIO_0000000&gt

      </pre>
  </section>
</section>
</body>
</html>



<!--  LocalWords:  AMIA OHDSI
 -->
<!--TODO: We need to review and include relevant material from the "Best Practices for Reporting  Preclinical Studies " section of
 https://alzped.nia.nih.gov/resources? -->
<!-- TODO: Possible Drop XML Section -->
